Clinical Pharmacokinetics

, Volume 32, Issue 3, pp 210–258 | Cite as

Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

  • Richard J. BertzEmail author
  • G. Richard Granneman
Review Article Drug Interactions


This article reviews the information available to assist pharmacokineticists in the prediction of metabolic drug interactions. Significant advances in this area have been made in the last decade, permitting the identification in early drug development of dominant cytochrome P450 (CYP) isoform(s) metabolising a particular drug as well as the ability of a drug to inhibit a specific CYP isoform. The major isoforms involved in human drug metabolism are CYP3A, CYP2D6, CYP2C, CYP1A2 and CYP2E1. Often patients are taking multiple concurrent medications, and thus an assessment of potential drug-drug interactions is imperative.

A database containing information about the clearance routes for over 300 drugs from multiple therapeutic classes, including analgesics, anti-infectives, psychotropics, anticonvulsants, cancer chemotherapeutics, gastrointestinal agents, cardiovascular agents and others, was constructed to assist in the semiquantitative prediction of the magnitude of potential interactions with drugs under development. With knowledge of the in vitro inhibition constant of a drug (Ki) for a particular CYP isoform, it is theoretically possible to assess the likelihood of interactions for a drug cleared through CYP-mediated metabolism. For many agents, the CYP isoform involved in metabolism has not been identified and there is substantial uncertainty given the current knowledge base.

The mathematical concepts for prediction based on competitive enzyme inhibition are reviewed in this article. These relationships become more complex if the inhibition is of a mixed competitive/noncompetitive nature. Sources of uncertainty and inaccuracy in predicting the magnitude of in vivo inhibition includes the nature and design of in vitro experiments to determine Ki, inhibitor concentration in the hepatic cytosol compared with that in plasma, prehepatic metabolism, presence of active metabolites and enzyme induction. The accurate prospective prediction of drug interactions requires rigorous attention to the details of the in vitro results, and detailed information about the pharmacokinetics and metabolism of the inhibitor and inhibited drug.

With the discussion of principles and accompanying tabulation of literature data concerning the clearance of various drugs, a framework for reasonable semiquantitative predictions is offered in this article.


Quinidine Ritonavir Clinical Pharmacokinetic Terfenadine Loratadine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1973; 1: 553–67Google Scholar
  2. 2.
    Mitra AK, Thummel KE, Kalhorn TF, et al. Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin Pharmacol Ther 1996; 59: 332–40PubMedGoogle Scholar
  3. 3.
    Kerr BM, Rettie AE, Eddy AC, et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther 1989; 46: 82–93PubMedGoogle Scholar
  4. 4.
    Kunze KL, Trager WF. Warfarin-Fluconazole III: a rational approach to management of a metabolically based drug interaction. Drug Metab Dispos 1996; 24: 429–35PubMedGoogle Scholar
  5. 5.
    Pisani F, Haj-Yehia A, Fazio A, et al. Carbamazepine-valnoctamide interaction in epileptic patients: In vitro/in vivo correlation. Epilepsia 1993; 34: 954–9PubMedGoogle Scholar
  6. 6.
    Kroetz DL, Loiseau P, Guyot M, et al. In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide. Clin Pharmacol Ther 1993; 54: 484–97Google Scholar
  7. 7.
    von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125–31Google Scholar
  8. 8.
    Iwatsubo T, Hirota N, Ooie T, et al. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 1996; 17: 273–310PubMedGoogle Scholar
  9. 9.
    Kroemer HK, Echizen H, Heidemann H, et al. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 1992; 260: 1052–7PubMedGoogle Scholar
  10. 10.
    Wu C-Y, Benet LZ, Herbert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492–7PubMedGoogle Scholar
  11. 11.
    Rolan PE. Plasma protein binding displacement interactions?: why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37: 125–8PubMedGoogle Scholar
  12. 12.
    Sellers EM. Plasma protein displacement interactions are rarely of clinical importance. Pharmacology 1979; 18: 225–7PubMedGoogle Scholar
  13. 13.
    Price-Evans DA, Mainley KA, McKussick VA. Genetic control of isoniazide metabolism in man. BMJ 1960; 2: 485–91Google Scholar
  14. 14.
    Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquin in man. Lancet 1977; II: 584–6Google Scholar
  15. 15.
    Eichelbaum M, Spannbrucker N, Steinchk B, et al. Defective N-oxidation of sparteine in man. Eur J Clin Pharmacol 1979; 16: 183–7PubMedGoogle Scholar
  16. 16.
    Kupper A, Desmond P, Schenker S, et al. Family study of a genetically determined deficiency of mephenytoin hydroxylation in man. Pharmacologist 1979; 21: 173Google Scholar
  17. 17.
    Gonzalez FJ. The molecular biology of cytochrome P450. Pharmacol Rev 1989; 40: 243–88Google Scholar
  18. 18.
    Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414–23PubMedGoogle Scholar
  19. 19.
    Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman and Gilmans the pharmacological basis of therapeutics. 9th ed. New York (NY): McGraw-Hill, 1996: 3–29Google Scholar
  20. 20.
    Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595–605PubMedGoogle Scholar
  21. 21.
    Guengerich FP, Maartin MV, Beaune PH, et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation: a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261: 5051–60PubMedGoogle Scholar
  22. 22.
    Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450 IIIA4. J Med Chem 1991; 34: 1838–44PubMedGoogle Scholar
  23. 23.
    Wrighton SA, Vandenbranden M. Isolation and characterization of human fetal liver cytochrome P450HLp2: a third member of the P450III gene family. Arch Biochem Biophys 1989; 268: 144–51PubMedGoogle Scholar
  24. 24.
    Wrighton SA, Ring BJ, Watkins PB, et al. Identification of a polymorphic ally expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989; 86: 97–105Google Scholar
  25. 25.
    Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38: 207–13PubMedGoogle Scholar
  26. 26.
    Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488–90PubMedGoogle Scholar
  27. 27.
    Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31: 47–64PubMedGoogle Scholar
  28. 28.
    Bailey DG, Arnold JMO, Munoz C, et al. Grapefruit juice-felodipine interaction: mechanism, predictability and effect of naringin. Clin Pharmacol Ther 1993; 53Google Scholar
  29. 29.
    Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44: 2089–98PubMedGoogle Scholar
  30. 30.
    Strobl GR, von Kruedener S, Stöckigt J, et al. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem 1993; 36: 1136–45PubMedGoogle Scholar
  31. 31.
    Kimura S, Umeno M, Skoda RC, et al. The human debrisoquine 4-hydroxylation (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and pseudogene. Am J Hum Genet 1989; 45: 889–90PubMedGoogle Scholar
  32. 32.
    Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquin/sparteine metabolism-clinical aspects. Pharmacol Ther 1990; 46: 377–94PubMedGoogle Scholar
  33. 33.
    Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquin/sparteine polymorphism. Clin Pharmacol Ther 1991; 50; 233–8PubMedGoogle Scholar
  34. 34.
    Johansson I, Lundqvist E, Bertilsson L. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of derisoquine. Proc Natl Acad Sci 1993; 90: 11825–9PubMedGoogle Scholar
  35. 35.
    Agúndez JA, Ledesma MC, Ladero JM, et al. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57: 265–9PubMedGoogle Scholar
  36. 36.
    Graf T, Broly F, Hoffmann F. Prediction of phenotype for acetylation and for debrisoquin hydroxylation by DNA tests in healthy human volunteers. Eur J Clin Pharmacol 1992; 43: 399–403PubMedGoogle Scholar
  37. 37.
    Dahl M-J, Johansson I, Palmertz MP, et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51: 12–7PubMedGoogle Scholar
  38. 38.
    Broly F, Gaedigk A, Heim M, et al. Debrisoquin/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991; 10: 545–58PubMedGoogle Scholar
  39. 39.
    Bertilsson L, Lou Y-Q, Du Y-L, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388–97PubMedGoogle Scholar
  40. 40.
    Kroemer HK, Eichelbaum M. ‘Its the genes stupid’: molecular basis and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995; 56: 2285–98PubMedGoogle Scholar
  41. 41.
    Shimoda K, Noguchi T, Morita S, et al. Interindividual variations of desmethylation and hydroxylation of amitriptyline in a Japanese psychiatric population. J Clin Psychopharmacol 1995; 15: 175–81PubMedGoogle Scholar
  42. 42.
    Schmider J, Greenblatt DJ, Von Moltke L, et al. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995; 275: 592–7PubMedGoogle Scholar
  43. 43.
    Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401–9PubMedGoogle Scholar
  44. 44.
    Brosen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 1993: 349–55Google Scholar
  45. 45.
    von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibition of desipramine hydroxylation in vitro by serotoninreuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994; 268: 1278–83Google Scholar
  46. 46.
    Rettie AE, Korzewaka KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-450-2C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54–9PubMedGoogle Scholar
  47. 47.
    Andersson T, Regardh CG, Dahl-Puustinen ML, et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monitor 1990; 12: 415–6Google Scholar
  48. 48.
    Andersson T, Regardh CG, Lou YC, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25–31PubMedGoogle Scholar
  49. 49.
    DeMorais SMF, Wilkinson GR, Blaisdell J, et al. A major genetic defect responsible for the polymorphism of S-mephentoin metabolism in humans. J Biol Chem 1994; 269: 15419–22PubMedGoogle Scholar
  50. 50.
    Caraco Y, Tateishi T, Wood AJJ. Interethnic difference in omeprazoles inhibition of diazepam metabolism. Clin Pharmacol Ther 1995; 58: 62–72PubMedGoogle Scholar
  51. 51.
    Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79–85PubMedGoogle Scholar
  52. 52.
    Andersson T, Andren K, Cederberg C, et al. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 1990; 39: 51–4PubMedGoogle Scholar
  53. 53.
    Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism: studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235–41PubMedGoogle Scholar
  54. 54.
    Kinonen T, Pasanen M, Gynther J, et al. Competitive inhibition of coumarin 7-hydroxylation by pilocarpine and its interaction with mouse CYP2A5 and human CYP2A6. Br J Pharmacol 1995; 116: 2625–30PubMedGoogle Scholar
  55. 55.
    Guengerich FP, Shimada T, Yun C-H, et al. Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes. Environ Health Perspect 1994; 102: 49–53PubMedGoogle Scholar
  56. 56.
    Daly AK, Cholerton S, Gregory W, et al. Metabolic polymorphisms. Pharmacol Ther 1993; 57: 129–60PubMedGoogle Scholar
  57. 57.
    Dahlqvist R, Bertilsson L, Birkett DJ, et al. Theophylline metabolism in relation to antipyrine, debrisoquin, and sparteine metabolism. Clin Pharmacol Ther 1984; 35: 815–21PubMedGoogle Scholar
  58. 58.
    Patten C, Thomas PE, Guy R, et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol 1993; 6: 511–8PubMedGoogle Scholar
  59. 59.
    Woolf TF, Pool WF, Kukan M, et al. Characterization of tacrine metabolism and bioactivation using heterologous expression systems and inhibition studies: evidence for CYP1A2 involvement [abstract no. 139]. 5th North American International Society for the Study of Xenobiotics Meeting; 1993 Oct 17–20; Tucson, Arizona. Bethesda (MD): International Society for the Study of Xenobiotics (ISSX) 4: 17–21Google Scholar
  60. 60.
    Bertilsson L, Carrillo JA, Dahl M-L, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471–3PubMedGoogle Scholar
  61. 61.
    Gu L, Gonzalez FJ, Kalow W, et al. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by c-DNA expressed human CYP1A2 and CYP1E1. Pharmacogenetics 1992; 2: 73–7PubMedGoogle Scholar
  62. 62.
    Wagner W, Vause EW. Fluvoxamine: a review of global drug-drug interaction data. Clin Pharmacokinet 1995; 29: 26–32PubMedGoogle Scholar
  63. 63.
    Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992; 6: 724–30PubMedGoogle Scholar
  64. 64.
    Böcker PR, Beaune PH, Iwasaki M, et al. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIE1. Chem Res Toxicol 1990; 3: 566–73PubMedGoogle Scholar
  65. 65.
    Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 2nd ed. Philadelphia (PA): Lea & Febiger, 1989: 386–91Google Scholar
  66. 66.
    Ereshefsky L, Riesenman C, Lam YWF. Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6. Clin Pharmacokinet 1995; 29: 10–9PubMedGoogle Scholar
  67. 67.
    von Moltke LL, Greenblatt D, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995; 29: 33–44Google Scholar
  68. 68.
    Leeman TD, Dayer P. Quantitative predictions of in vivo drug metabolism and interactions from in vitro data. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism. Brussels: European Commision, 1995: 785–830Google Scholar
  69. 69.
    Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987; 39: 1–47PubMedGoogle Scholar
  70. 70.
    Yata N, Toyoda T, Murakami T, et al. Phosphatidylserine as a determinant for the tissue distribution of weakly basic drugs. Pharm Res 1990; 10: 1019–25Google Scholar
  71. 71.
    Shet MS, Faulkner KM, Holmans PL, et al. The effects of cytochrome b5, NADPH-450 reductase and lipid on the rate of 6β-hydroxylation of testosterone as catalyzed by human P450 3A4 fusion protein. Arch Biochem Biophys 1995; 318: 314–21PubMedGoogle Scholar
  72. 72.
    Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26: 144–60PubMedGoogle Scholar
  73. 73.
    Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15–9PubMedGoogle Scholar
  74. 74.
    Herbert MF, Roberts JP, Prueksaritanont T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453–7Google Scholar
  75. 75.
    Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129–34PubMedGoogle Scholar
  76. 76.
    Arias IM. Multidrug resistance genes, P-glycoprotein and the liver. Hepatology 1990; 12: 159–65PubMedGoogle Scholar
  77. 77.
    Cato A, Cavanaugh JH, Shi H, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin [abstract Mo.B.1199]. XI International Conference on AIDS; 1996 Jul 7–12: VancouverGoogle Scholar
  78. 78.
    Ouellet D, Hsu A, Granneman GR, et al. Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1996; 59: 143Google Scholar
  79. 79.
    Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 1990; 45: 241–98PubMedGoogle Scholar
  80. 80.
    Barry M, Feely J. Enzyme induction and inhibition. Pharmacol Ther 1990; 48: 71–94PubMedGoogle Scholar
  81. 81.
    Luoma PV. Enzyme induction, lipids, and apolipoproteins. In: Sotaniemi EA, Pelkonen RO, editors. Enzyme induction in man. Bristol (PA): Taylor & Francis, 1987: 231–42Google Scholar
  82. 82.
    Hsu A, Granneman GR, Witt G, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [Abstract Mo.B.1200]. XI International Conference on AIDS; 1996 Jul 7–12; VancouverGoogle Scholar
  83. 83.
    Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers [Abstract Mo.B.1198]. XI International Conference on AIDS; 1996 Jul 7–12; VancouverGoogle Scholar
  84. 84.
    Cato III A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and zidovudine [Abstract I34]. 35th ICAAC Annual Meeting 1995; 1995 Sept 17–20; San FranciscoGoogle Scholar
  85. 85.
    Sarker MA, Jackson BJ. Theophylline N-demethylations as probes for P450 1A1 and P450 1A2. Drug Metab Dispos 1994; 22: 827–34Google Scholar
  86. 86.
    Branigan TA, Robins RA, Cady WJ, et al. The effects of erythromycin on the absorption and disposition kinetics of theophylline. Eur J Clin Pharmacol 1981; 21: 115–20PubMedGoogle Scholar
  87. 87.
    Weinberger M, Hudgel D, Spector S, et al. Inhibition of theophylline clearance by troleandomycin. J Allergy Clin Immunol 1977; 59: 228–31PubMedGoogle Scholar
  88. 88.
    Cramer KF, Secor J, Speeg KV. The effect of the of administration of the cimetidine-theophylline drug interaction. J Clin Pharmacol 1989; 29: 451–6Google Scholar
  89. 89.
    Sörgel F, Mahr G, Granneman GR, et al. Effects of 2 quinolone antibacterials, temafloxin and enoxacin on theophylline pharmacokinetics. Clin Pharmacokinet 1992; 22: 65–74PubMedGoogle Scholar
  90. 90.
    Granneman GR, Braeckman RA, Locke CS, et al. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 1995; 29: 77–83PubMedGoogle Scholar
  91. 91.
    Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 1994; 55: 481–5PubMedGoogle Scholar
  92. 92.
    Zhou H-H, Anthony LB, Roden DM, et al. Quinidine reduces clearance of (+)-propranolol more than (−)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther 1990; 47: 686–93PubMedGoogle Scholar
  93. 93.
    Muralidharan G, Cooper JK, Hawes EM, et al. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolizers. Eur J Clin Pharmacol 1996; 50: 121–8PubMedGoogle Scholar
  94. 94.
    Yun CH, Wood M, Wood AJ, et al. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. Anesthesiology 1992; 77: 467–74PubMedGoogle Scholar
  95. 95.
    Labroo RB, Thummel KE, Kunze KL, et al. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995; 23: 490–6PubMedGoogle Scholar
  96. 96.
    Olkkola KT, Hamunen K, Maunuksela E-L. Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin Pharmacokinet 1995; 28: 385–404PubMedGoogle Scholar
  97. 97.
    Cleary J, Mikus G, Somogyi A, et al. The influence of pharmacogenetics on opoid analgesia: Studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. J Pharmacol Exp Ther 1994; 271: 1528–34PubMedGoogle Scholar
  98. 98.
    Yue Q-Y, Svennson J-O, Säwe J, et al. Codeine metabolism in three Oriental populations: a pilot study in Chinese, Japanese and Koreans. Pharmacogenetics 1995; 5: 173–7PubMedGoogle Scholar
  99. 99.
    Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5: 335–46PubMedGoogle Scholar
  100. 100.
    Sindrup SH, Hofmann U, Asmussen J, et al. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. Eur J Clin Pharmacol 1996; 49: 503–9PubMedGoogle Scholar
  101. 101.
    Caraco Y, Tateishi T, Guengerich FP, et al. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab Dispos 1996; 24: 761–4PubMedGoogle Scholar
  102. 102.
    Tateishi T, Wood AJJ, Guengerich FP, et al. Biotransformation of tritiated fentanyl in human liver microsomes. Monitoring metabolism using phenylacetic acid and 2-phenylethanol. Biochem Pharmacol 1995; 50: 1921–4PubMedGoogle Scholar
  103. 103.
    Tateishi T, Krivoruk Y, Ueng Y-F, et al. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil n-dealkylation. Anesth Analg 1996; 82: 167–72PubMedGoogle Scholar
  104. 104.
    Rop PP, Grimaldi F, Burle J, et al. Determination of 6-monoacetylmorphine and morphine in plasma, whole blood and urine using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1994; 661: 245–53PubMedGoogle Scholar
  105. 105.
    Inturrisi CE, Max MB, Foley KM. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 1984; 310: 1213–7PubMedGoogle Scholar
  106. 106.
    Otton SV, Schadel M, Cheung SW, et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1995; 54: 463–72Google Scholar
  107. 107.
    Hagen N, Thirwell MP, Dhaliwal HS, et al. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate controlled-release hydromorphone. J Clin Pharmacol 1995; 35: 37–44PubMedGoogle Scholar
  108. 108.
    Kuttab SH, Nowshad F, Shargel L. Effect of phenobarbital pretreatment on the plasma and urinary levels of (−)-alpha-acetylmethadol and its metabolites. J Pharm Sci 1985; 74: 331–44PubMedGoogle Scholar
  109. 109.
    Houghton IT, Chan K, Wong YC, et al. Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. Methods Find Exp Clin Pharmacol 1992; 14: 451–8PubMedGoogle Scholar
  110. 110.
    Mather LE, Meffin PJ. Clinical pharmcokinetics pethidine. Clin Pharmacokinet 1978; 3: 352–68PubMedGoogle Scholar
  111. 111.
    Pond SM, Tong T, Benowitz NL, et al. Presystemic metabolism of meperidine to normeperidine in normal cirrhotic subjects. Clin Pharmacol Ther 1981; 30: 183–8PubMedGoogle Scholar
  112. 112.
    Danzinger LH, Martin SJ, Blum RA. Central nervous system toxicity associated with meperidine use in hepatic disease. Pharmacotherapy 1994; 14: 235–8Google Scholar
  113. 113.
    Green MD, Tephly TR. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab Dispos 1996; 24: 356–63PubMedGoogle Scholar
  114. 114.
    Iribarne C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9: 365–73PubMedGoogle Scholar
  115. 115.
    Inturrisi CE, Colburn WA, Kaiko RF, et al. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41: 392–401PubMedGoogle Scholar
  116. 116.
    Handal KA, Schauben JL, Salamone FR. Naloxone. Ann Emerg Med 1983; 12: 438–45PubMedGoogle Scholar
  117. 117.
    Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35: 192–213PubMedGoogle Scholar
  118. 118.
    Ohara H, Miyabe Y, Deyashiki Y, et al. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver. Biochem Pharmacol 1995; 50: 221–7PubMedGoogle Scholar
  119. 119.
    Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996; 59: 52–61PubMedGoogle Scholar
  120. 120.
    Inturrisi CE, Colbum WA, Verebey K. Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. Clin Pharmacol Ther 1982; 31: 157–67PubMedGoogle Scholar
  121. 121.
    Sanz EJ, Bertilsson L. D-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo. Ther Drug Monitor 1990; 12: 297–9Google Scholar
  122. 122.
    Paar WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. Clin Invest 1992; 70: 708–10Google Scholar
  123. 123.
    Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993; 46: 313–40PubMedGoogle Scholar
  124. 124.
    Thummel KE, Lee CA, Kunze KL, et al. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993; 45: 1563–9PubMedGoogle Scholar
  125. 125.
    Thomsen MS, Loft S, Roberts DW, et al. Cytochrome P4502E1 inhibition by propylene glycol prevents acetaminophen (paracetamol) hepatotoxicity in mice without cytochrome P4501A2 inhibition. Pharmacol Toxicol 1995; 76: 395–9PubMedGoogle Scholar
  126. 126.
    Dai Y, I CA. Cytotoxicity of acetaminophen in human cytochrome P4502E1-transfected hepG2 cells. J Pharmacol Exp Ther 1995; 273: 1497–505PubMedGoogle Scholar
  127. 127.
    Bochner F, Graham GG, Cham E, et al. Salicylate metabolite kinetics after several salicylates. Clin Pharmacol Ther 1981; 30: 266–75PubMedGoogle Scholar
  128. 128.
    Ding RW, Kolbe K, Merz B, et al. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther 1989; 46: 642–7PubMedGoogle Scholar
  129. 129.
    Willis JV, Kendall MJ, Flinn RM, et al. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol 1979; 16: 405–10PubMedGoogle Scholar
  130. 130.
    Leemann TD, Transon C, Bonnabry P, et al. A major role for cytochrome P450tb (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drug Exp Clin Res 1993; 19: 189–95Google Scholar
  131. 131.
    Goldstein JA, de Morias SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285–99PubMedGoogle Scholar
  132. 132.
    Tracy TS, Rosenbluth BW, Wrighton SA, et al. Role of cytochrome P450 2C9 and an allelic variant in the 4-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 1995; 49: 1269–75PubMedGoogle Scholar
  133. 133.
    Davies NM. Clinical pharamcokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 1995; 28: 100–14PubMedGoogle Scholar
  134. 134.
    Lee EJD, Williams K, Day R, et al. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 1985; 19: 669–74PubMedGoogle Scholar
  135. 135.
    Oberbauer R, Krivanek P, Turnheim K. Pharmacokinetics of indomethacin in the elderly. Clin Pharmacokinet 1993; 24: 428–34PubMedGoogle Scholar
  136. 136.
    Jamali F, Brocks DR. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 1990; 19: 197–217PubMedGoogle Scholar
  137. 137.
    Dubois-Presle N, Lapicque F, Maurice M-H, et al. Stereoselective esterase activity of human serum albumin toward ketoprofen glucuronide. Mol Pharmacol 1995; 47: 647–63PubMedGoogle Scholar
  138. 138.
    Brocks DR, Jamali F. Clinical pharmacokinetics of ketorolac tromethamine. Clin Pharmacokinet 1992; 23: 415–27PubMedGoogle Scholar
  139. 139.
    Hyneck ML. An overview of the clinical pharmacokinetics of nabumetone. J Rheumatol 1992; 19: 20–4Google Scholar
  140. 140.
    Vree TB, Van Den Biggelaar-Martea M, Verwey-Van Wissen CPWGM, et al. The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl-glucuronides in humans, Effect of cimetidine. Br J Clin Pharmacol 1993; 35: 467–72PubMedGoogle Scholar
  141. 141.
    Rodrigues AD, Kukulka MJ, Roberts EM, et al. [O-Methyl-14C]Naproxen O-demethylase activity in human liver microsomes. Drug Metab Dispos 1996; 24: 126–36PubMedGoogle Scholar
  142. 142.
    Miners JO, Coulter S, Tukey RH, et al. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 1996; 51: 1003–8PubMedGoogle Scholar
  143. 143.
    Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet 1994; 26: 107–20PubMedGoogle Scholar
  144. 144.
    Lauritsen K, Laursen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Pt II). Clin Pharmacokinet 1990; 19: 94–125PubMedGoogle Scholar
  145. 145.
    Ravis WR, Diskin CJ, Campagna KD, et al. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure. J Clin Pharmacol 1993; 33: 527–34PubMedGoogle Scholar
  146. 146.
    Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. Biochem Pharmacol 1994; 47: 1969–79PubMedGoogle Scholar
  147. 147.
    Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36: S8–S13PubMedGoogle Scholar
  148. 148.
    Backman JT, Olkkola KT, Ojala M, et al. Concentration and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37: 253–7PubMedGoogle Scholar
  149. 149.
    Svinarov DA, Pippenger CE. Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase? Ther Drug Monitor 1995; 17: 217–20Google Scholar
  150. 150.
    Bachman K, Chang AC, Greear V. In vivo evidence that ethosuximide is a substrate for cytochrome P450IIIA. Pharmacology 1992; 45: 121–8Google Scholar
  151. 151.
    Bauer LA, Harris C, Wilensky AJ, et al. Ethosuximide kinetics: possible interaction with valproic acid. Clin Pharmacol Ther 1982; 31: 741–5PubMedGoogle Scholar
  152. 152.
    Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet 1993; 24: 441–52PubMedGoogle Scholar
  153. 153.
    Ramsay RE, Pellock JM, Garnett WR. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991; 10: 191–200PubMedGoogle Scholar
  154. 154.
    Reidenberg P, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of phénobarbital. Clin Pharmacol Ther 1995; 58: 279–87PubMedGoogle Scholar
  155. 155.
    Murayama N, Shimada M, Yamazoe Y, et al. Distinct effects of phenobarbital and its n-methylated derivative on liver cytochrome P450 induction. Arch Biochem Biophys 1996; 328: 184–92PubMedGoogle Scholar
  156. 156.
    Donato MT, Castell JV, Gómez-Lechón MJ. Effect of model inducers on cytochrome P450 activities of human liver hepatocytes in primary culture. Drug Metab Dispos 1995; 23: 553–8PubMedGoogle Scholar
  157. 157.
    Kupfer A, Branch RA. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 1985; 38: 414–8PubMedGoogle Scholar
  158. 158.
    Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31: 125–30PubMedGoogle Scholar
  159. 159.
    Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995; 58: 617–24PubMedGoogle Scholar
  160. 160.
    Levine M, Chang T. Therapeutic drug monitoring of phenytoin: rationale and current status. Clin Pharmacokinet 1990; 19: 341–58PubMedGoogle Scholar
  161. 161.
    Sadeque AJM, Korzekwa KR, Gonzalez FJ, et al. Identification of human liver cytochrome P450 isozymes responsible for the formation of 4-ene valproic acid. Vol. 6. Fourth International International Society for the Study of Xenobiotics Meeting; 1995 Aug 27–31; Seattle: 87Google Scholar
  162. 162.
    Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994; 47: 332–72PubMedGoogle Scholar
  163. 163.
    Rettie AE, Sheffels PR, Korzekwa KR, et al. CYP4 isozyme specificity and the relationship between ω-hydroxylation and terminal desaturation of valproic acid. Biochemistry 1995; 34: 7889–95PubMedGoogle Scholar
  164. 164.
    Bauer LA, Blouin RA. Influence of age on amikacin pharmacokinetics in patients without renal disease comparison with gentamicin and tobramycin. Eur J Clin Pharmacol 1983; 24: 639–42PubMedGoogle Scholar
  165. 165.
    Sjövall J, Alván G, Huitfeldt B. Intra- and inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers. Br J Clin Pharmacol 1986; 21: 171–81PubMedGoogle Scholar
  166. 166.
    Lalak NJ, Morris DL. Azithromycin: clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 370–4PubMedGoogle Scholar
  167. 167.
    Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106–31PubMedGoogle Scholar
  168. 168.
    Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450–82PubMedGoogle Scholar
  169. 169.
    Klepser ME, Marangos MN, Patel KB, et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet 1995; 28: 361–84PubMedGoogle Scholar
  170. 170.
    Robson RA. The effects of quinolones on xanthine pharmacokinetics. Am J Med 1992; 92: 22S–25SPubMedGoogle Scholar
  171. 171.
    Borcherding SM, Stevens R, Nicholas RA, et al. Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. J Fam Prac 1996; 42: 69–78Google Scholar
  172. 172.
    Freeman CD, Nicolau DP, Belliveau PP, et al. Lomefloxacin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 6–19PubMedGoogle Scholar
  173. 173.
    Sörgel F, Jaehde U, Naber K, et al. Pharmacokinetic disposition of quinolones in human body fluids and tissues. Clin Pharmacokinet 1989; 16: 5–24PubMedGoogle Scholar
  174. 174.
    Lamp KC, Bailey EM, Rybak MJ. Ofloxacin clinical pharmacokinetics. Clin Pharmacokinet 1992; 22: 32–46PubMedGoogle Scholar
  175. 175.
    Vance-Bryan K, Guay DRP, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19: 434–61PubMedGoogle Scholar
  176. 176.
    Wallace RJ, Brown BA, Griffith DE, et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995; 171: 747–50PubMedGoogle Scholar
  177. 177.
    Plaisance KI, Drusano GL, Forrest A, et al. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother 1989; 33: 618–20PubMedGoogle Scholar
  178. 178.
    Vöhringer H-F, Arastéh K. Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia. Clin Pharmacokinet 1993; 24: 388–412PubMedGoogle Scholar
  179. 179.
    Raghuram TC, Krishnaswamy K. Pharmacokinetics of tetracycline in nutritional ocdema. Chemotherapy 1982; 28: 428–33PubMedGoogle Scholar
  180. 180.
    Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988; 15: 355–66PubMedGoogle Scholar
  181. 181.
    Lown KS, Thummel KE, Benedict PE, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995: 16–24Google Scholar
  182. 182.
    Hunt CM, Watkins PB, Saenger P, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992; 51: 18–23PubMedGoogle Scholar
  183. 183.
    Zhang X-J, Thomas PE. Erythromycin as a specific substrate for cytochrome P4503A isozymes and identification of a high-affinity erythromycin N-demethylase in adult female rats. Drug Metab Dispos 1996; 24: 23–7PubMedGoogle Scholar
  184. 184.
    Buckley MM, Brogden RN, Barradell LB, et al. Imipenem/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992; 44: 408–44PubMedGoogle Scholar
  185. 185.
    Lau AH, Lam NP, Piscitelli SC, et al. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23: 328–64PubMedGoogle Scholar
  186. 186.
    Marshall JP II, Salt WB, Elam RO, et al. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction. Gastroenterology 1977; 73: 1388–92PubMedGoogle Scholar
  187. 187.
    Dittert LW, Griffen WO Jr, LaPiana JC, et al. Pharmacokinetic interpretation of penicillin levels in serum and urine after intravenous administration. Antimicrob Agents Chemother 1969; 9: 42–8PubMedGoogle Scholar
  188. 188.
    Leader WG, Chandler MHH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995; 28: 327–42PubMedGoogle Scholar
  189. 189.
    Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308–29PubMedGoogle Scholar
  190. 190.
    Duhm B, Medenwald H, Maul W. The pharmacokinetics of clotrimazole 14C. Postgrad Med J 1974; 50: 13–6PubMedGoogle Scholar
  191. 191.
    Gombert ME, DuBouchet L, Aulicino TM, et al. A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplants. Use in prophylaxix of oropharyngeal candidiasis. JAMA 1987; 258: 2553–5PubMedGoogle Scholar
  192. 192.
    Debruyne D, Ryckelynck J-P. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993; 24: 10–27PubMedGoogle Scholar
  193. 193.
    Kunze KL, Weinkers LC, Thummel KE, et al. Warfarin-Fluconazole I: inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996; 24: 414–21PubMedGoogle Scholar
  194. 194.
    Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-Fluconazole II: a metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422–8PubMedGoogle Scholar
  195. 195.
    Cutler RE, Blair AD, Kelly MR. Flucytosine kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 1978; 24: 333–42PubMedGoogle Scholar
  196. 196.
    Baldwin SJ, Bloomer JC, Smith GJ, et al. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261–70PubMedGoogle Scholar
  197. 197.
    Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 1995; 27: 397–417PubMedGoogle Scholar
  198. 198.
    Badcock NR, Bartholomeusz FD, Frewin DB, et al. The pharmacokinetics of ketoconazole after chronic administration in adults. Eur J Clin Pharmacol 1987; 33: 531–4PubMedGoogle Scholar
  199. 199.
    Moore LW, Alloway RR, Acchiardo SR, et al. Clinical observations of metabolic changes occurring in renal transplant recipients receiving ketoconazole. Transplantation 1996; 61: 537–41PubMedGoogle Scholar
  200. 200.
    OReilly RA, Goulart DA, Kunze KL, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992; 51: 656–7Google Scholar
  201. 201.
    Back DJ, Tha JF, Abel SM. Azoles, allylamines and drug metabolism. Br J Dermatol 1992; 126: 14–8PubMedGoogle Scholar
  202. 202.
    Humbert H, Cabiac MD, Denouèl J, et al. Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Biopharm Drug Dispos 1995; 16: 685–94PubMedGoogle Scholar
  203. 203.
    Kovarik JM, Kirkesseli S, Humbert H, et al. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 1992; 126: 8–13PubMedGoogle Scholar
  204. 204.
    Kovarik JM, Mueller E, A., Zehender H, et al. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother 1995; 39: 2738–41PubMedGoogle Scholar
  205. 205.
    Garrelts JC. Clofazimine: A review of its use in leprosy and Mycobacterium avium complex infection. DICP Ann Pharmacother 1991; 25: 525–31Google Scholar
  206. 206.
    Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9: 511–44PubMedGoogle Scholar
  207. 207.
    Israili ZH, Rogers CM, El-Attar H. Pharmacokinetics of anti-tuberculosis drugs in patients. J Clin Pharmacol 1987; 27: 78–83PubMedGoogle Scholar
  208. 208.
    Zand R, Nelson SD, Slattery JT, et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993; 54: 142–9PubMedGoogle Scholar
  209. 209.
    Gibaldi M. Pharmacogenetics: Part I. Ann Pharmacother 1992; 26: 121–6PubMedGoogle Scholar
  210. 210.
    Nasako Y, Yamamoto T, Moriwaki Y, et al. In vitro and in vivo study on the conversion of allopurinol and pyrazinamide. Adv Exp Med Biol 1996; 370: 43–6Google Scholar
  211. 211.
    Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996; 22: S15–S22PubMedGoogle Scholar
  212. 212.
    Benedetti MS, Dostert P. Induction and autoinduction properties of rifamycin derivatives: A review of animal and human studies. Environ Health Perspect 1994; 109: 101–5Google Scholar
  213. 213.
    Borcherding SM, Bastian TL, Self TH, et al. Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism. Antimicrob Agents Chemother 1992; 36: 1553–8PubMedGoogle Scholar
  214. 214.
    Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59: 7–13PubMedGoogle Scholar
  215. 215.
    Gottschall DW, Theorides VJ, Wang R. The metabolism of benzimidazole anthelmintics. Parasitol Today 1990; 6: 115–24PubMedGoogle Scholar
  216. 216.
    Marriner SE, Morris DL, Dickson B, et al. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacokinet 1986; 30: 705–8Google Scholar
  217. 217.
    Villaverde C, Alvarez AI, Redondo P, et al. Small intestinal sulphoxidation of albendazole. Xenobiotica 1995; 25: 433–41PubMedGoogle Scholar
  218. 218.
    Moroni P, Buronfosse T, Longin-Sauvageon C, et al. Chiral sulfoxidation of albendazole by the flavin adenine dinucleotide-containing and cytochrome P450-dependent monoxygenases from rat liver microsomes. Drug Metab Dispos 1995; 23: 160–5PubMedGoogle Scholar
  219. 219.
    Spencer CM, Goa KL. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs 1995; 50: 176–96PubMedGoogle Scholar
  220. 220.
    Lee BL, Täuber MG, Sadler B, et al. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther 1996; 59: 14–21PubMedGoogle Scholar
  221. 221.
    Masimerembwa CM, Hasler JA, Johansoon I. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6. Eur J Clin Pharmacol 1995; 48: 35–8Google Scholar
  222. 222.
    Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 1996; 30: 263–99PubMedGoogle Scholar
  223. 223.
    Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 1996; 31: 257–74PubMedGoogle Scholar
  224. 224.
    Palamanda JR, Hickman D, Ward A, et al. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs. Drug Metab Dispos 1995; 23: 473–7PubMedGoogle Scholar
  225. 225.
    Mitra AK, Thummel KE, Kalhorn T, et al. Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 1995; 58: 556–66PubMedGoogle Scholar
  226. 226.
    Gill HJ, Tingle MD, Park BK. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: Implications for inhibition of haemotoxicity. Br J Clin Pharmacol 1995; 40: 531–8PubMedGoogle Scholar
  227. 227.
    Stein CM, Kinirons MT, Pincus T, et al. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996; 59: 47–51PubMedGoogle Scholar
  228. 228.
    Berman JD, Fleckenstein L. Pharmacokinetic justification of antiprotozoal therapy: A US perspective. Clin Pharmacokinet 1991; 21: 479–92PubMedGoogle Scholar
  229. 229.
    Campbell WC. Ivermectin, an antiparasitic agent. Med Res Rev 1993; 13: 61–79PubMedGoogle Scholar
  230. 230.
    Ette EI, Thomas WOA, Achumba JI. Ivermectin: a long-acting microfilaricidal agent. DICP Ann Pharmacother 1990; 24: 426–33Google Scholar
  231. 231.
    Witassek F, Burkhardt B, Eckert J, et al. Chemotherapy of alveolar echinococcosis: comparison of plasma mebendazole concentrations in animals and man. Eur J Clin Pharmacokin 1981; 20: 427–33Google Scholar
  232. 232.
    Braithwaite PA, Roberts MS, Allan RJ, et al. Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. Eur J Clin Pharmacol 1982; 22: 161–9PubMedGoogle Scholar
  233. 233.
    Palmer KJ, Holliday SM, Brogden RN. Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45: 430–75PubMedGoogle Scholar
  234. 234.
    Edwards G, Winstanley PA, Ward SA. Clinical pharmacokinetics in the treatment of tropical diseases: some applications and limitations. Clin Pharmacokinet 1994; 27: 150–65PubMedGoogle Scholar
  235. 235.
    Bissuel F, Cotte L, De Montclos M, et al. Absence of systemic absorption of oral paromomycin during long-term, high-dose treatment for cryptosporidiosis in AIDS (5). J Infect Dis 1994; 170: 749–50PubMedGoogle Scholar
  236. 236.
    Conte Jr JE. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis 1991; 163: 169–75PubMedGoogle Scholar
  237. 237.
    King CH, Mahmoud AAF. Drugs five years later: praziquantel. Ann Intern Med 1989; 110: 290–6PubMedGoogle Scholar
  238. 238.
    Fletcher KA, Price Evans DA, Gilles HM, et al. Studies on the pharmacokinetics of primaquine. Bull World Health Organ 1981; 59: 407–12PubMedGoogle Scholar
  239. 239.
    Mihaly GW, Ward SA, Edwards G, et al. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacokinet 1984; 17: 441–6Google Scholar
  240. 240.
    Wright JD, Helsby NA, Ward SA. The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol 1995; 39: 441–4PubMedGoogle Scholar
  241. 241.
    Birkett DJ, Rees D, Andersson T, et al. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994; 37: 413–20PubMedGoogle Scholar
  242. 242.
    Helsbey NA, Ward SA, Howells RE, et al. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br J Clin Pharmacol 1990; 30: 287–91Google Scholar
  243. 243.
    Skjelbo E, Mutabingwa TK, Bygbjerg I, et al. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996; 59: 304–11PubMedGoogle Scholar
  244. 244.
    Winstanley PA, Watkins WM, Newton CRJC, et al. The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe Falciparum malaria. Br J Clin Pharmacokinet 1992; 33: 143–8Google Scholar
  245. 245.
    Watkins PJ, Gorrod JW. Determination of isomeric N-oxide metabolites of some substituted 2,4-diaminopyrimidines by reverse-phase ion-pair high-performance liquid chromatography. J Chromatogr 1993; 616: 79–85PubMedGoogle Scholar
  246. 246.
    Bjorkman S, Elisson LO, Gabrielsson J. Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man. J Pharm Pharmacol 1989; 41: 160–3PubMedGoogle Scholar
  247. 247.
    Steiner E, Dumont E, Spina E, et al. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther 1987; 43: 577–81Google Scholar
  248. 248.
    Bergan T, Örtengren B, Westerlund D. Clinical pharmacokinetics of co-trimazine. Clin Pharmacokinet 1986; 11: 372–86PubMedGoogle Scholar
  249. 249.
    Oie S, Gambertoglio JG, Fleckenstein L. Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing. J Pharmacokinet Biopharm 1982; 10: 157–72PubMedGoogle Scholar
  250. 250.
    Cribb AE, Spielberg SP, Griffin GP. N4-Hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 1995; 23: 406–14PubMedGoogle Scholar
  251. 251.
    Chin TWF, Vanderbroucke A, Fong IW. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother 1995; 39: 28–33PubMedGoogle Scholar
  252. 252.
    Bauer LA, Raisys VA, Watts MT, et al. The pharmacokinetics of thiabendazole and its metabolites in an anephric patient undergoing hemodialysis and hemoperfusion. J Clin Pharmacol 1982; 22: 276–80PubMedGoogle Scholar
  253. 253.
    Fulton B, Wagstaff AJ, McTavish D. Trimetrexate: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of Pneumocystis carinii pneumonia. Drugs 1995; 49: 563–76PubMedGoogle Scholar
  254. 254.
    Dudley MN. Clinical pharmacokinetics of nucleoside anti-retroviral agents. J Infect Dis 1995; 171: S99–S112PubMedGoogle Scholar
  255. 255.
    Faulds D, Brogden RN. Didanosine: A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 1992; 44: 94–116PubMedGoogle Scholar
  256. 256.
    Chiba M, Hensleigh M, Nishime JA, et al. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996; 24: 307–14PubMedGoogle Scholar
  257. 257.
    Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996; 51: 701–12PubMedGoogle Scholar
  258. 258.
    Yuen GJ, Morris DM, Mydlow PK, et al. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol 1995; 35: 1174–80PubMedGoogle Scholar
  259. 259.
    Pluda JM, Cooley TP, Montaner JSG, et al. A phase I/II study of 2-deoxy-3thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995; 171: 1438–47PubMedGoogle Scholar
  260. 260.
    Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423–31PubMedGoogle Scholar
  261. 261.
    Cretton EM, Zhou Z, Kidd LB, et al. In vitro and in vivo dispositon and metabolism of 3-deoxy-2,3-didehydrothymidine. Antimicrob Agents Chemother 1993; 37: 1816–25PubMedGoogle Scholar
  262. 262.
    Sommadossi J-P. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2,3-dideoxynucleoside analogues. J Infect Dis 1995; 171: S88–S92PubMedGoogle Scholar
  263. 263.
    Devineni D, Gallo JM. Zalcitabine: Clinical pharmacokinetics and efficacy. Clin Pharmacokinet 1995; 28: 351–60PubMedGoogle Scholar
  264. 264.
    Veal GJ, Barry MG, Back DJ. Zalcitabine (ddC) phosphorylation and drug interactions. Antiviral Chemistry Chemother 1995; 6: 379–84Google Scholar
  265. 265.
    Eagling VA, Howe JL, Barry MJ, et al. The metabolism of zidovudine by human liver microsomes in vitro: formation of 3-amino-3-deoxythymidine. Biochem Pharmacol 1994; 48: 267–76PubMedGoogle Scholar
  266. 266.
    Veal GJ, Back DJ. Metabolism of zidovudine. Gen Pharmacol 1995; 26: 1469–75PubMedGoogle Scholar
  267. 267.
    Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinetics of zidovudine: An update. Clin Pharmacokinet 1996; 30: 251–62PubMedGoogle Scholar
  268. 268.
    Rolan P. Pharmacokinetics of new antiherpetic agents. Clin Pharmacokinet 1995; 29: 333–40PubMedGoogle Scholar
  269. 269.
    Morse GD, Shelton MJ, ODonnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 1993; 24: 101–23PubMedGoogle Scholar
  270. 270.
    Lalezari JP, Drew WL, Glutzer E, et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): Results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995; 171: 788–96PubMedGoogle Scholar
  271. 271.
    Clarke SE, Harrell AW, Chenery RJ. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 1995; 23: 251–4PubMedGoogle Scholar
  272. 272.
    Aweeka FT, Gambertoglio JG, Kramer F, et al. Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. Clin Pharmacol Ther 1995; 57: 403–12PubMedGoogle Scholar
  273. 273.
    Whitley R, Alford C, Hess F, et al. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs 1980; 47: 267–82Google Scholar
  274. 274.
    Takeda A, Higuchi D, Yamamoto T, et al. Purification and characterization of bleomycin hydrolase, which represents a new family of cysteine proteases, from rat skin. J Biochem 1996; 119: 29–36PubMedGoogle Scholar
  275. 275.
    Yee GC, Crom WR, Lee FH, et al. Bleomycin disposition in children with cancer. Clin Pharmacol Ther 1983; 33: 668–73PubMedGoogle Scholar
  276. 276.
    Chen L, Waxman DJ, Chen D, et al. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996; 56: 1331–40PubMedGoogle Scholar
  277. 277.
    Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interaction. Br J Clin Pharmacol 1995; 40: 523–30PubMedGoogle Scholar
  278. 278.
    Moreb J, Schweder M, Suresh A, et al. Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther 1996; 3: 24–30PubMedGoogle Scholar
  279. 279.
    Chang TKH, Weber GF, Crespi CL, et al. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629–37PubMedGoogle Scholar
  280. 280.
    Balis FM, Holcenberg JS, Bleyer WA. Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 1983; 8: 202–32PubMedGoogle Scholar
  281. 281.
    Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993; 17: 219–51PubMedGoogle Scholar
  282. 282.
    Doyle LA, Ross DD, Sridhara R, et al. Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. Br J Cancer 1995; 71: 52–8PubMedGoogle Scholar
  283. 283.
    Rushing DA, Raber SR, Rodvold KA, et al. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994; 74: 834–41PubMedGoogle Scholar
  284. 284.
    Relling MV, Nemec J, Schuetz EG, et al. O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45: 352–8PubMedGoogle Scholar
  285. 285.
    Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987; 12: 223–52PubMedGoogle Scholar
  286. 286.
    Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215–37PubMedGoogle Scholar
  287. 287.
    Villani P, Maserati R, Regazzi MB, et al. Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. J Clin Pharmacol 1996; 36: 117–21PubMedGoogle Scholar
  288. 288.
    Boddy AV, Cole M, Pearson ADJ, et al. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995; 36: 53–60PubMedGoogle Scholar
  289. 289.
    Kurowski V, Cerny T, Küpfer A, et al. Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 1991; 117: S148–S153PubMedGoogle Scholar
  290. 290.
    Wills RJ. Clinical pharmcokinetics of interferons. Clin Pharmacokinet 1990; 19: 390–9PubMedGoogle Scholar
  291. 291.
    Israel BC, Blouin RA, McIntyre W, et al. Effects of interferon-α monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229–35PubMedGoogle Scholar
  292. 292.
    Bannwarth B, Péhourcq F, Schaeverbeke T, et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194–210PubMedGoogle Scholar
  293. 293.
    Sonnichsen DS, Relling MV. Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 1994; 27: 256–69PubMedGoogle Scholar
  294. 294.
    Jamis-Dow CA, Klecker RW, Katki AG, et al. Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 1995; 35: 107–14Google Scholar
  295. 295.
    Kumar G, Ray S, Walle T, et al. Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6α-hydroxytaxol. Cancer Chemother Pharmacol 1995; 36: 129–35PubMedGoogle Scholar
  296. 296.
    Sonnichsen DS, Liu Q, Schuetz EG, et al. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 566–75PubMedGoogle Scholar
  297. 297.
    Mani C, Pearce R, Parkinson A, et al. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis 1994; 15: 2715–20PubMedGoogle Scholar
  298. 298.
    Peyrade F, Frenay M, Etienne M-C, et al. Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 1996; 59: 401–10PubMedGoogle Scholar
  299. 299.
    Williams ML, Lennard MS, Martin IJ, et al. Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. Carcinogenesis 1994; 15: 2733–8PubMedGoogle Scholar
  300. 300.
    Zhou-Pan X-R, Sérée E, Zhou X-J, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53: 5121–6PubMedGoogle Scholar
  301. 301.
    Rahmani R, Zhou X-J. Pharmacokinetics and metabolism of Vinca alkaloids. Cancer Surv 1993; 17: 269–81PubMedGoogle Scholar
  302. 302.
    Kelley JG, OMalley K. Clinical pharmacokinetics of the newer ACE inhibitors. A review. Clin Pharmacokinet 1990; 19: 177–96Google Scholar
  303. 303.
    Duchin KL, McKinstry DN, Cohen AI, et al. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin Pharmacokinet 1988; 14: 241–59PubMedGoogle Scholar
  304. 304.
    MacFadyen RJ, Meredith PA, Elliott HL. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1993; 25: 274–82PubMedGoogle Scholar
  305. 305.
    Ford NF, Lasseter KC, Van Harken DR, et al. Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. J Clin Pharmacol 1995; 35: 145–50PubMedGoogle Scholar
  306. 306.
    Fabre G, Julian B, Saint-Aubert B, et al. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 1995; 21: 978–85Google Scholar
  307. 307.
    Gill J, Heel RC, Fitton A. Amiodarone: an overview of its pharmacological properties and review of its therapeutic use in cardiac arrhythmias. Drugs 1992; 43: 69–110PubMedGoogle Scholar
  308. 308.
    Ito S, Woodland C, Harper PA, et al. The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1). Life Sci 1993; 53: PL399–PL403PubMedGoogle Scholar
  309. 309.
    Mooradian AD. Digitalis: an update of clinical pharmacokinetics, therapeutic monmitoring techniques, and treatment recommendations. Clin Pharmacokinet 1988; 15: 165–79PubMedGoogle Scholar
  310. 310.
    Siddoway LA, Woosley RL. Clinical pharmacokinetics of disopyramide. Clin Pharmacokinet 1986; 11214–222Google Scholar
  311. 311.
    Echizen H, Kawasaki H, Chiba K, et al. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. J Pharmacol Exp Ther 1993; 264: 1425–31PubMedGoogle Scholar
  312. 312.
    Wang T, Wolfenden HT, Woosley RL, et al. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther 1984; 228: 605–11PubMedGoogle Scholar
  313. 313.
    Funck-Bretano C, Thomas G, Jacqz-Aigrain E, et al. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 1992; 263: 780–5Google Scholar
  314. 314.
    Beckmann J, Hertrampf R, Gundert-Remy U, et al. Is there a genetic factor in flecainide toxicity? BMJ 1988; 297: 1316PubMedGoogle Scholar
  315. 315.
    Funck-Brentano C, Becquemont L, Kroemer HK, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994; 55: 256–69PubMedGoogle Scholar
  316. 316.
    Iamoko S, Enomoto K, Oda Y, et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. J Pharmacol Exp Ther 1990; 255: 1385–91Google Scholar
  317. 317.
    Nattel S, Gagne G, Pineau M. The pharmacokinetics of lignocaine and β-adrenoceptor antagonists in patients with acute myocardial infarction. Clin Pharmacokinet 1987; 13: 293–316PubMedGoogle Scholar
  318. 318.
    Turgeon J, Fiset C, Giguère R, et al. Influence of debrisoquin phenotype and of quinidine on mexiletine disposition in man. J Pharmacol Exp Ther 1991; 259: 789–98PubMedGoogle Scholar
  319. 319.
    Lima JJ, Conti DR, Goldfarb AL. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. J Pharmacokinet Biopharm 1979; 7: 69–85PubMedGoogle Scholar
  320. 320.
    Atkinson AJ Jr, Ruo TI, Piergies AA, et al. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method. Clin Pharmacol Ther 1989; 46Google Scholar
  321. 321.
    Kroemer HK, Fischer C, Meese CO, et al. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: In vitro evaluation of the mechanism. Mol Pharmacol 1991; 40: 135–42PubMedGoogle Scholar
  322. 322.
    Mörike K, Magadum S, Mettang T, et al. Propafenone in a usual dose produces severe side-effects: The impact of genetically determined metabolic status on drug therapy. J Intern Med 1995; 238: 469–72PubMedGoogle Scholar
  323. 323.
    Kroemer HK, Mikus G, Kronbach T, et al. In vitro characterisation of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 1989; 45: 28–33PubMedGoogle Scholar
  324. 324.
    Siddoway LA, Thompson KA, McAllister CB, et al. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences. Circulation 1987; 75: 785–91PubMedGoogle Scholar
  325. 325.
    Spinier SS, Cheng JWM, Kindwall KE, et al. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 1995; 57: 89–94Google Scholar
  326. 326.
    Ching MS, Blake CL, Ghabrial H, et al. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine and its metabolites. Biochem Pharmacol 1995; 50: 833–7PubMedGoogle Scholar
  327. 327.
    Guengerich FP, Müller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986; 30: 287–95PubMedGoogle Scholar
  328. 328.
    Verme CN, Ludden TM, Clementi WA, et al. Pharmacokinetics of quinidine in male patients: A population analysis. Clin Pharmacokinet 1992; 22: 468–80PubMedGoogle Scholar
  329. 329.
    Hippius M, Henschel L, Sigusch H, et al. Pharmacokinetic interactions of nifedipine and quinidine. Pharmazie 1995; 50: 613–6PubMedGoogle Scholar
  330. 330.
    Brinn R, Brøsen K, Gram LF, et al. Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 1986; 22: 194–7PubMedGoogle Scholar
  331. 331.
    Roden DM, Woosley RL. Drug therapy. Tocainide. N Engl J Med 1986; 315: 41–5PubMedGoogle Scholar
  332. 332.
    Estes JW. Clinical pharmacokinetics of heparin. Clin Pharmacokinet 1980; 5: 204–20PubMedGoogle Scholar
  333. 333.
    Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22: 359–74PubMedGoogle Scholar
  334. 334.
    de Boer A, van Griensven JMT. Drug interactions with thrombolytic agents. Clin Pharmacokinet 1995; 28: 315–26PubMedGoogle Scholar
  335. 335.
    Hermans JJR, Thyssen HHW. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumaral: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 1993; 110: 482–90PubMedGoogle Scholar
  336. 336.
    He M, Kunze KL, Trager WF. Inhibition of (S)-warfarin metabolism by sulflnpyrazone and its metabolites. Drug Metab Dispos 1995; 23: 659–63PubMedGoogle Scholar
  337. 337.
    Zhang Z, Fasco MJ, Huang Z, et al. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab Dispos 1995; 23: 1339–45PubMedGoogle Scholar
  338. 338.
    Wienkers LC, Wurden CJ, Storch E, et al. Formation of (R)-8-hydroxywarfarin in human liver microsomes. Drug Metab Dispos 1996; 24: 610–4PubMedGoogle Scholar
  339. 339.
    Salazar DE, Dockens RC, Milbrath RL, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995; 35: 730–8PubMedGoogle Scholar
  340. 340.
    Singh BN, Thoden WR, Wahl J. Acebutolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects. Pharmacotherapy 1986; 6: 45–63PubMedGoogle Scholar
  341. 341.
    Ebihara A, Fujimura A. Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1991; 21: 331–43PubMedGoogle Scholar
  342. 342.
    Lewis RV, Lennard MS, Jackson PR, et al. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1985; 19: 329–33PubMedGoogle Scholar
  343. 343.
    Lennard MS, Tucker GT, Silas JH, et al. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 1986; 16: 435–77PubMedGoogle Scholar
  344. 344.
    Frishman WH, Tepper D, Lazar EJ, et al. Betaxolol: A new long-acting beta1-selective adrenergic blocker. J Clin Pharmacol 1990; 30Google Scholar
  345. 345.
    Leopold G, Pabst J, Unethüm W, et al. Basic pharmacokinetics of bisoprolol, a new highly beta1-selective adrenoceptor antagonist. J Clin Pharmacol 1986; 26: 616–21PubMedGoogle Scholar
  346. 346.
    Sennello LT, Finley RA, Chu S-Y, et al. The effect of impaired renal function on the multiple dose clinical pharmacokinetics of carteolol. Adv Ther 1987; 4: 298–308Google Scholar
  347. 347.
    Donnelly R, Macphee GJA. Clinical pharmacokinetics and kinetic-dynamic relationships of delevalol and labetalol. Clin Pharmacokinet 1991; 21: 95–109PubMedGoogle Scholar
  348. 348.
    Mautz D, Nelson WL, Shen DD. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Drug Metab Dispos 1995; 23: 513–7PubMedGoogle Scholar
  349. 349.
    Johnson JA, Burlew BS. Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 1996; 24: 350–5PubMedGoogle Scholar
  350. 350.
    Leemann TP, Dayer P, Meyer UA. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolisers. Eur J Clin Pharmacol 1986; 29: 739–41PubMedGoogle Scholar
  351. 351.
    Lennard MS, Tucker GT, Silas JH, et al. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther 1983; 34: 732–7PubMedGoogle Scholar
  352. 352.
    McGourty JC, Silas JH, Lennard MS, et al. Metoprolol metabolism and debrisoquine oxidation polymorphism: population and family studies. Br J Clin Pharmacol 1985; 20: 555–66PubMedGoogle Scholar
  353. 353.
    Lennard MS, Silas JH, Freestone S, et al. Oxidation phenotype: a major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307: 1558–60PubMedGoogle Scholar
  354. 354.
    Morrison RA, Singhvi SM, Creasey WA, et al. Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects. Eur J Clin Pharmacol 1988; 33: 625–8PubMedGoogle Scholar
  355. 355.
    Lennard MS, Tucker GT, Woods HF. The polymorphic oxidation of beta-adrenoceptor antagonists: clinical pharmacokinetic considerations. Clin Pharmacokinet 1986; 11: 1–17PubMedGoogle Scholar
  356. 356.
    Frishman WH, Lazar EJ, Gorodokin G. Pharmacokinetic optimisation of therapy with beta-adrenergic blocking agents. Clin Pharmacokinet 1991; 20: 311–8PubMedGoogle Scholar
  357. 357.
    Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1984; 34: 73–80PubMedGoogle Scholar
  358. 358.
    Guerret M, Cheymol G, Aubry JP, et al. Estimation of the absolute oral bioavailability of pindolol by two analytical methods. Eur J Clin Pharmacol 1983; 25: 357–9PubMedGoogle Scholar
  359. 359.
    Lennard MS, Jackson PR, Freestone S, et al. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 1984; 39: 679–85Google Scholar
  360. 360.
    Colangelo PM, Blouin RA, Steinmetz JE, et al. Age and propranolol stereoselective disposition in humans. Clin Pharmacol Ther 1992; 51: 489–94PubMedGoogle Scholar
  361. 361.
    Yoshimoto K, Echizen H, Chiba K, et al. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers: N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 1995; 39: 421–31PubMedGoogle Scholar
  362. 362.
    Ching MS, Bichara N, Blake CL, et al. Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2. Drug Metab Dispos 1996; 24: 692–4PubMedGoogle Scholar
  363. 363.
    Ward SA, Walle T, Walle K, et al. Propranolols metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989; 45: 72–9PubMedGoogle Scholar
  364. 364.
    Antonaccio MJ, Gomoll A. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. Am J Cardiol 1990; 65: 12A-21AGoogle Scholar
  365. 365.
    Haria M, Wagstaff AJ. Amlodipine. Areappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50: 560–86PubMedGoogle Scholar
  366. 366.
    Awni WM, Halstenson CE, Nayak RK, et al. Pharmacokinetics of bepridil and two of its metabolites in patients with end-stage renal disease. J Clin Pharmacol 1995; 35: 379–83PubMedGoogle Scholar
  367. 367.
    Pichard L, Gillet G, Fabre I, et al. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos 1990; 18: 711–9PubMedGoogle Scholar
  368. 368.
    Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995; 104: 1–8PubMedGoogle Scholar
  369. 369.
    Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996; 59: 369–75PubMedGoogle Scholar
  370. 370.
    Bailey DG, Bend JR, Arnold MO, et al. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996; 60: 25–33PubMedGoogle Scholar
  371. 371.
    Brogden RN, Sorkin EM. Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs 1995; 49: 618–49PubMedGoogle Scholar
  372. 372.
    Singh BN, Josephson MA. Clinical pharmacology, pharmacokinetics and hemodynamic effects of nicardipine. Am Heart J 1990; 119: 427–34PubMedGoogle Scholar
  373. 373.
    Laurent-Kenesi M-A, Funck-Brentano C, Poirier J-M, et al. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol 1993; 36: 531–8PubMedGoogle Scholar
  374. 374.
    Ahsan CH, Renwick AG, Waller DG, et al. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 329–38PubMedGoogle Scholar
  375. 375.
    Yamazaki H, Nakano M, Imai Y, et al. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch Biochem Biophys 1996; 325: 174–82PubMedGoogle Scholar
  376. 376.
    Grundy JS, Foster RT. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and parmacological properties. Clin Pharmacokinet 1996; 30: 28–51PubMedGoogle Scholar
  377. 377.
    Mück W, Ahr G, Kuhlmann J. Nimodipine: potential for drug drug interactions in the elderly. Drugs Aging 1995; 6: 229–42PubMedGoogle Scholar
  378. 378.
    Davidsson GK, Edwards JS, Davidson C. The effect of age and liver disease on the pharmacokinetics of the calcium antagonist, nisoldipine. Curr Med Res Opin 1995; 13: 285–97PubMedGoogle Scholar
  379. 379.
    Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet 1994; 26: 91–8PubMedGoogle Scholar
  380. 380.
    Soons PA, Breimer DD. Stereoselective pharmacokinetics of oral intravenous nitrendipine in healthy male subjects. Br J Clin Pharmacol 1991; 32: 11–6PubMedGoogle Scholar
  381. 381.
    Busse D, Cosme J, Beaune P, et al. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmeidebergs Arch Pharmacol 1995; 353: 116–21Google Scholar
  382. 382.
    Gupta SK, Hwang S, Atkinson L, et al. Simultaneous first-order and capacity-limited elimination kinetics after oral administration of verapamil. J Clin Pharmacol 1996; 36: 25–34PubMedGoogle Scholar
  383. 383.
    Spina E, Avenoso A, Campo GM, et al. Decreased plasma concentrations of imipramine and desipramine following cholestyramine intake in depressed patients. Ther Drug Monitor 1994; 16: 432–4Google Scholar
  384. 384.
    Gugler R, Kurten JW, Jensen CJ, et al. Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol 1979; 15: 341–7PubMedGoogle Scholar
  385. 385.
    Tse FLS, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992; 32: 630–8PubMedGoogle Scholar
  386. 386.
    Smith HT, Jokubaitis LA, Troendle A-J, et al. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993; 6: 375S–382SPubMedGoogle Scholar
  387. 387.
    Transon C, Leemann T, Vogt N, et al. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin Pharmacol Ther 1995; 58: 412–7PubMedGoogle Scholar
  388. 388.
    Sallustio BC, Foster DJR. Reactivity of gemfibrozil 1-O-β-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts in rats. Drug Metab Dispos 1995; 23: 892–9PubMedGoogle Scholar
  389. 389.
    Todd PA, Ward A. Gemfibrozil, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dislipidaemia. Drugs 1988; 36: 314–39PubMedGoogle Scholar
  390. 390.
    Wang RW, Kari PH, Lu AYH, et al. Biotransformation of lovastatin: identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991; 290: 355–61PubMedGoogle Scholar
  391. 391.
    McKenney JM. Lovastatin: a new cholesterol-lowering agent. Clin Pharmacokinet 1988; 7: 21–36Google Scholar
  392. 392.
    Neuvonen P, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54–61PubMedGoogle Scholar
  393. 393.
    Quion JAV, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994; 27: 94–103PubMedGoogle Scholar
  394. 394.
    Horsmans Y, Desager JP, Van den Berge V, et al. Effects of simvastatin and pravastatin on 6-beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A. Pharmacol Res 1993; 28: 243–8PubMedGoogle Scholar
  395. 395.
    Pan HY, Waclawski AP, Funke PT, et al. Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 1993; 27: 1029–33PubMedGoogle Scholar
  396. 396.
    Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993; 24: 195–202PubMedGoogle Scholar
  397. 397.
    Plosker GL, McTavish D. Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1995; 50: 334–63PubMedGoogle Scholar
  398. 398.
    Lowenthal DT, Matzek KM, MacGregor TR. Clinical pharmacokinetics of clonidine. Clin Pharmacokinet 1988; 14: 287–310PubMedGoogle Scholar
  399. 399.
    Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin: An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295–320PubMedGoogle Scholar
  400. 400.
    Boles Ponto LL, Schoenwald RD. Furosemide (Frusemide): A pharmacokinetic/pharmacodynamic review (Pt I). Clin Pharmacokinet 1990; 18: 381–408Google Scholar
  401. 401.
    Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977; 12: 297–303PubMedGoogle Scholar
  402. 402.
    Bennett BM, McDonald BJ, Nigam R, et al. Biotransformation of organic nitrates and vascular smooth muscle cell function. Trends Pharmacol Sci 1994; 15: 245–9PubMedGoogle Scholar
  403. 403.
    Stearns RA, Chakravarty PK, Chen R, et al. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23: 207–15PubMedGoogle Scholar
  404. 404.
    Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641–9PubMedGoogle Scholar
  405. 405.
    Goldberg MR, Lo MW, Deutch PJ, et al. Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clin Pharmacol Ther 1996; 59: 268–74PubMedGoogle Scholar
  406. 406.
    Vincent J, Meredith PA, Reid JL, et al. Clinical pharmacokinetics of prazosin-1985. Clin Pharmacokinet 1985; 10: 144–54PubMedGoogle Scholar
  407. 407.
    Lenz ML, Pool J,L, Laddu AR, et al. Combined terazosin and verapamil therapy in essential hypertension: hemodynamic and pharmacokinetic interactions. Am J Hypertens 1995; 8: 133–45PubMedGoogle Scholar
  408. 408.
    Miners JO, Rees DLP, Veronese ME, et al. Involvement of human liver microsomal cytochrome P450 2C9 in torasemide hydroxylation. Clin Exp Pharmacol Physiol 1993: 49Google Scholar
  409. 409.
    Dunn CJ, Fitton A, Brogden RN. Torasemide: An update of its pharmacological properties and therapeutic efficacy. Drugs 1995; 49: 121–42PubMedGoogle Scholar
  410. 410.
    Gilfrich HJ, Kremer G, Möhrke W, et al. Pharmacokinetics of triamterene after iv administration to man: determination of bioavailability. Eur J Clin Pharmacol 1983; 25: 237–41PubMedGoogle Scholar
  411. 411.
    Muirhead MR, Somogyi AA, Rolan PE, et al. Effect of cimetidine on renal and hepatic drug elimination: studies with triamterene. Clin Pharmacol Ther 1986; 40: 400–7PubMedGoogle Scholar
  412. 412.
    Desager J-P, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. Clin Pharmacokinet 1995; 28: 419–32PubMedGoogle Scholar
  413. 413.
    Salata JJ, Jurkiewicz NK, Wallace AA, et al. Cardiac electrophysical actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilaminè. Circ Res 1995; 76: 110–9PubMedGoogle Scholar
  414. 414.
    Heykants J, Van Peer A, Woestenborghs R, et al. Dose-proportionality, bioavailability, and steady-state kinetics of astemizole in man. Drug Development Res 1986; 8: 71–8Google Scholar
  415. 415.
    Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985; 10: 477–97PubMedGoogle Scholar
  416. 416.
    Simons FER, Frith EM, Simons KJ. The pharmacokinetics and antihistaminic effects of brompheniramine. J Allergy Clin Immunol 1982; 70: 458–64PubMedGoogle Scholar
  417. 417.
    Hiroi T, Ohishi N, Imaoka S, et al. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. J Pharmacol Exp Ther 1995; 272: 939–43PubMedGoogle Scholar
  418. 418.
    Spencer CM, Faulds D, Peters DH. Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs 1993; 46: 1055–80PubMedGoogle Scholar
  419. 419.
    Simons FER, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol 1995; 95: 685–93PubMedGoogle Scholar
  420. 420.
    Carlston JA. Drug interactions and the cytochrome P-450 enzymes. Pediatric Asthma, Allergy Immunol 1995; 9: 123–32Google Scholar
  421. 421.
    Huang S-M, Athanikar NK, Sridhar K, et al. Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. Eur J Clin Pharmacol 1982; 22: 359–65PubMedGoogle Scholar
  422. 422.
    Luo H, Hawes EM, McKay G, et al. N+-Glucuronidation of aliphatic tertiary amines, a general phenomenon in the metabolism of H1-antihistamines in humans. Xenobiotica 1991; 21: 1281–8PubMedGoogle Scholar
  423. 423.
    Blyden GT, Greenblatt DJ, Scavone JM, et al. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. J Clin Pharmacol 1986; 26: 529–33PubMedGoogle Scholar
  424. 424.
    Simons FER, Simons KJ, Frith EM. The pharmacokinetics and antihistaminic effects of the H1-receptor antagonist hydroxyzine. J Allergy Clin Immunol 1984; 73: 69–75PubMedGoogle Scholar
  425. 425.
    Brannan MD, Reidenberg P, Radwanski E, et al. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995; 58: 269–78PubMedGoogle Scholar
  426. 426.
    Yumibe N, Huie K, Chen K-J, et al. Identification of human liver cytochrome P450 enzymes that metabolize the non-sedating antihistamine loratadine. Biochem Pharmacol 1996; 51: 165–72PubMedGoogle Scholar
  427. 427.
    Haley TJ. Physical and biological properties of pyrilamine. J Pharm Sci 1983; 72: 3–12PubMedGoogle Scholar
  428. 428.
    Chung BC, Kim DH, Jung BH, et al. Identification of urinary metabolites of pyrilamine after oral administration to man. Xenobiotica 1994; 24: 451–9PubMedGoogle Scholar
  429. 429.
    Ling K-HJ, Leeson GS, Burmaster SD, et al. Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab Dispos 1995; 23: 631–6PubMedGoogle Scholar
  430. 430.
    von Moltke LL, Greenblatt DJ, Duan SX, et al. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994; 34: 1222–7Google Scholar
  431. 431.
    Rodrigues AD, Mulford DJ, Lee RD, et al. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Drug Metab Dispos 1995; 23: 765–75PubMedGoogle Scholar
  432. 432.
    Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383–8PubMedGoogle Scholar
  433. 433.
    von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996; 16: 104–12Google Scholar
  434. 434.
    Yun C-H, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993; 21: 403–9PubMedGoogle Scholar
  435. 435.
    Simons KJ, Singh M, Gillespie CA, et al. An investigation of the H1-receptor antagonist triprolidine: pharmacokinetics and antihistaminic effects. J Allergy Clin Immunol 1986; 77: 326–30PubMedGoogle Scholar
  436. 436.
    Inaba T. Cocaine: Pharmacokinetics and biotransformation in man. Can J Physiol Pharmacol 1989; 67: 1154–7PubMedGoogle Scholar
  437. 437.
    LeDuc BW, Sinclair PR, Shuster L, et al. Norcaine and N-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3 A4. Pharmacology 1993; 46: 294–300Google Scholar
  438. 438.
    Pasanen M, Pellinen P, Stenbäck F, et al. The role of CYP enzymes in cocaine-induced liver damage. Arch Toxicol 1995; 69: 287–90PubMedGoogle Scholar
  439. 439.
    Gross AS, Phillips AC, Rieutord A, et al. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Br J Clin Pharmacol 1996; 41: 311–7PubMedGoogle Scholar
  440. 440.
    Gorski JC, Jones DR, Wrighton SA, et al. Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 1994; 48: 173–82PubMedGoogle Scholar
  441. 441.
    Schadel M, Wu D, Otton V, et al. Pharmacokinetics of dextromethorphan and metabolites in humans: Influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol 1995; 15: 263–9PubMedGoogle Scholar
  442. 442.
    Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 1996; 678: 113–8PubMedGoogle Scholar
  443. 443.
    Vanakoski J, Strömberg C, Seppälä T. Effects of a sauna on the pharmacokinetics and pharmacodynamics of midazolam and ephedrine in healthy young women. Eur J Clin Pharmacol 1993; 45: 377–81PubMedGoogle Scholar
  444. 444.
    Lin LY, Kumagai Y, Hiratsuka A, et al. Cytochrome P4502D isozymes catalyze the 4-hydroxylation of methamphetamine enantiomers. Drug Metab Dispos 1995; 23:610–4PubMedGoogle Scholar
  445. 445.
    Wargin W, Patrick K, Kilts C. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 1983; 226: 382–6PubMedGoogle Scholar
  446. 446.
    Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy 1993; 13: 116S–128SPubMedGoogle Scholar
  447. 447.
    Scherzinger SS, Dowse R, Kanfer I. Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects. J Clin Pharmacol 1990; 30: 372–7PubMedGoogle Scholar
  448. 448.
    Slichenmeyer WJ, Donehower RC, Chen T-L, et al. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. Cancer Chemother Pharmacol 1995; 36: 227–32Google Scholar
  449. 449.
    Smallwood RA, Berlin RG, Castagnoli N, et al. Safety of acid-suppressing drugs. Dig Dis Sci 1995; 40: 63S–80SPubMedGoogle Scholar
  450. 450.
    Levine M, Bellward GD. Effect of cimetidine on hepatic cytochrome P450: Evidence for formation of a metabolite-intermediate complex. Drug Metab Dispos 1995; 23: 1407–11PubMedGoogle Scholar
  451. 451.
    Lauritsen K, Laursen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Pt I). Clin Pharmacokinet 1990; 19: 11–31PubMedGoogle Scholar
  452. 452.
    Pearce RE, Rodrigues AD, Goldstein JA, et al. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277: 805–16PubMedGoogle Scholar
  453. 453.
    Pichard L, Curi-Pedrosa R, Bonfils C, et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995; 47: 410–8PubMedGoogle Scholar
  454. 454.
    Landes BD, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28: 458–70PubMedGoogle Scholar
  455. 455.
    Rost KL, Brösicke H, Brockmöller J, et al. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1995; 52: 170–80Google Scholar
  456. 456.
    Petersen K-U. Review article: omeprazole and the cytochrome P450 system. Aliment Pharmacol Ther 1995; 9: 1–9PubMedGoogle Scholar
  457. 457.
    Rost KL, Brockmöller J, Esdorn F, et al. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 1995; 23: 268–77PubMedGoogle Scholar
  458. 458.
    Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521–30PubMedGoogle Scholar
  459. 459.
    Sohn D-R, Kobayashi K, Chiba K, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262: 1195–202PubMedGoogle Scholar
  460. 460.
    Russell JL. Relatively low doses of cisapride in the treatment of nausea in patients treated with venlafaxine for treatmentrefractory depression. J Clin Psychopharmacol 1996; 16: 35–7PubMedGoogle Scholar
  461. 461.
    Ahmad SR, Wolfe SM. Cisapride and torsades de pointes. Lancet 1995; 345: 508Google Scholar
  462. 462.
    Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116–52PubMedGoogle Scholar
  463. 463.
    Watanabe K, Matsunaga T, Yamamoto I, et al. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 1995; 18: 1138–41PubMedGoogle Scholar
  464. 464.
    Yamamoto I, Watanabe K, Narimatsu S, et al. Recent advances in the metabolism of cannabinoids. Int J Cell Biol 1995; 27: 741–6Google Scholar
  465. 465.
    Bateman DN, Kahn C, Davies DS. The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Pharmacol 1980; 9: 371–7Google Scholar
  466. 466.
    Maurich V, De Amici M, De Micheli C, et al. Identification and full characterization of a new metabolite of metoclopramide. Eur J Med Chemistry 1995; 30: 757–62Google Scholar
  467. 467.
    Ashforth EIL, Palmer JL, Bye A, et al. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br J Clin Pharmacol 1994; 37: 389–91PubMedGoogle Scholar
  468. 468.
    Fischer V, Vickers AEM, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondasetron. Drug Metab Dispos 1994; 22: 269–74PubMedGoogle Scholar
  469. 469.
    Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995; 29: 95–109PubMedGoogle Scholar
  470. 470.
    Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995; 23: 1225–30PubMedGoogle Scholar
  471. 471.
    Midha KK, Marder SR, Jaworski TJ, et al. Clinical perspectives of some neuroleptics through development and application of their assays. Ther Drug Monitor 1993; 15: 179–89Google Scholar
  472. 472.
    Sridhar KS, Krishan A, Samy TSA, et al. Prochlorperazine as a doxorubicin-efflux blocker: Phase I clinical and pharmacokinetics studies. Cancer Chemother Pharmacol 1993; 31: 423–30PubMedGoogle Scholar
  473. 473.
    Lehr KH, Damm P. Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. J Chromatogr 1990; 526: 497–505PubMedGoogle Scholar
  474. 474.
    Abramowicz M. Glimepiride for NIDDM. The Med Lett 1996; 38: 47–50Google Scholar
  475. 475.
    Kobayashi KA, Bauer LA, Horn JR, et al. Glipizide pharmacokinetics in young and elderly volunteers. Clin Pharmacokinet 1988; 7: 224–8Google Scholar
  476. 476.
    Jonsson A, Rydberg T, Ekberg G, et al. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142–5PubMedGoogle Scholar
  477. 477.
    Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16: 195–202PubMedGoogle Scholar
  478. 478.
    Dunn CJ, Peters DH. Metformin: A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721–49PubMedGoogle Scholar
  479. 479.
    Balant L. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet 1981; 6: 215–41PubMedGoogle Scholar
  480. 480.
    Back DJ, Tjia JF, Karbwang J, et al. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988; 26: 23–9PubMedGoogle Scholar
  481. 481.
    Keuzenkamp-Jansen CW, De Abreu RA, Bökkerink JPM, et al. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma. J Pediatric Hematol Oncol 1996; 18: 145–50Google Scholar
  482. 482.
    Henricsson S, Lindholm A, Aravolglou M. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol Toxicol 1990; 66: 49–52PubMedGoogle Scholar
  483. 483.
    Lampen A, Christians U, Bader A, et al. Drug interactions and interindividual variability of cyclosporin metabolism in the small intestine. Pharmacology 1996; 52: 159–68PubMedGoogle Scholar
  484. 484.
    Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: Identification of a cytochrome P450III gene family as the major cyclosporine metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630–5PubMedGoogle Scholar
  485. 485.
    Campana C, Regazzi MB, Buggia I, et al. Clinically significant drug interactions with cyclosporin, an update. Clin Pharmacokinet 1996; 30: 141–79PubMedGoogle Scholar
  486. 486.
    Sattler M, Guengerich FP, Yun C-H, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753–61PubMedGoogle Scholar
  487. 487.
    Yatscoff RW, Wang P, Chan K, et al. Rapamycin: Distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monitor 1995; 17: 666–71Google Scholar
  488. 488.
    Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187–90PubMedGoogle Scholar
  489. 489.
    Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315–24PubMedGoogle Scholar
  490. 490.
    Matsuda H, Iwasaki K, Shiraga T, et al. Interactions of FK506 (tacrolimus) with clinically important drugs. Res Commun Mol Pathol Pharmacol 1996; 91: 57–64PubMedGoogle Scholar
  491. 491.
    Jusko WJ, Piekoszewski W, Klintmalm GB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281–90PubMedGoogle Scholar
  492. 492.
    El-Yazigi A, Chaleby K, Gad A, et al. Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol 1995; 35: 17–21PubMedGoogle Scholar
  493. 493.
    Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995; 31: 347–53PubMedGoogle Scholar
  494. 494.
    Bouchez J, Dumur V, Lhermitte M, et al. Genotypes of cytochrome P450 and clinical response to clomipramine in patients with major depression. Euro Psychiatry 1995; 10: 410–2Google Scholar
  495. 495.
    Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991; 20: 447–62PubMedGoogle Scholar
  496. 496.
    Balant-Gorgia AE, Balant LP, C. G, et al. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. J Clin Pharmacol 1986; 31Google Scholar
  497. 497.
    Conus P, Bondolfi G, Eap CB, et al. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Pharmacopyschiatry 1996; 29: 108–10Google Scholar
  498. 498.
    Kramir K, Flinois JP, Beaune P, et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996; 277: 1659–64Google Scholar
  499. 499.
    Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51: 239–48PubMedGoogle Scholar
  500. 500.
    Brosen K, Gram LF. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol 1989; 37: 155–60PubMedGoogle Scholar
  501. 501.
    von Bahr C, Spina E, Birgersson C, et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 1985; 34: 2501–5Google Scholar
  502. 502.
    Brosen K, Gram LF. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1988; 43: 400–6PubMedGoogle Scholar
  503. 503.
    Romiti P, Giuliani L, Pacifici GM. Interindividual variability in the N-sulphation of desipramine in human liver and platelets. Br J Clin Pharmacokinet 1992; 33: 17–23Google Scholar
  504. 504.
    Spina E, Avenoso A, Campo GM, et al. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monitor 1996; 18: 60–4Google Scholar
  505. 505.
    Faulkner RD, Pitts WM, Lee CS, et al. Multiple-dose doxepin kinetics in depressed patients. Clin Pharmacol Ther 1983; 34: 509–15PubMedGoogle Scholar
  506. 506.
    Ereshefsky L, Tran-Johnson T, Davis CM, et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: Evaluation of doxepin and imipramine. New data and review. Clin Chem 1988; 34: 863–80PubMedGoogle Scholar
  507. 507.
    Madsen H, Kramer N,K, Brosen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms: a population study. Br J Clin Pharmacol 1995; 39: 433–9PubMedGoogle Scholar
  508. 508.
    Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34: 256–61PubMedGoogle Scholar
  509. 509.
    Koyama E, Sohn D-R, Shin S-G, et al. Metabolic disposition of imipramine in Oriental subjects; relation to metropolol α-hydroxylation and S-mephenytoin 4-hydroxylation phenotypes. J Pharmacol Exp Ther 1994; 271: 860–7PubMedGoogle Scholar
  510. 510.
    Albers LJ, Reist C, Helmeste D, et al. Paroxetine shifts imipramine metabolism. Psychiatry Res 1996; 59: 189–96PubMedGoogle Scholar
  511. 511.
    Sutfin TA, Perini GI, Molnar G, et al. Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. J Clin Psychopharmacol 1988; 8: 48–53PubMedGoogle Scholar
  512. 512.
    Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993; 43: 827–32PubMedGoogle Scholar
  513. 513.
    Mellström B, Bertilsson L, Säwe J, et al. E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981; 30: 189–93PubMedGoogle Scholar
  514. 514.
    Bertilsson L, Eichelbaum M, Mellström B, et al. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980; 27: 1673–7PubMedGoogle Scholar
  515. 515.
    Leinonen E, Koponen HJ, Lepola U. Paroxetine increases serum trimipramine concentration. A report of two cases. Human Psychopharmacology 1995; 10: 345–7Google Scholar
  516. 516.
    Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995; 15: 327–33PubMedGoogle Scholar
  517. 517.
    Ascher JA, Cole JO, Colin J-N, et al. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395–401PubMedGoogle Scholar
  518. 518.
    Ring BJ, Binkley SN, Roskos L, et al. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995; 275: 1131–5PubMedGoogle Scholar
  519. 519.
    Levinson ML, Lipsy RJ, Fuller DK. Adverse effects and drug interactions and associated with fluoxetine therapy. DICP Ann Pharmacother 1991; 25: 657–61Google Scholar
  520. 520.
    Bulton B, McTavish D. Fluoxetine: an overview of its pharmacodynamic and pharmacokinetic properties and review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs 1995; 3: 305–22Google Scholar
  521. 521.
    Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P 450. J Pharmacol Exp Ther 1993; 266: 964–71PubMedGoogle Scholar
  522. 522.
    Kobayashi K, Yamamoto T, Chiba K, et al. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995; 40: 481–5PubMedGoogle Scholar
  523. 523.
    Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60: 512–21PubMedGoogle Scholar
  524. 524.
    van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29: 1–9PubMedGoogle Scholar
  525. 525.
    Spina E, Caputi AP. Pharmacogenetic aspects in the metabolism of psychotropic drugs: Pharmacokinetic and clinical implications. Pharmacol Res 1994; 29: 121–37PubMedGoogle Scholar
  526. 526.
    Rasmussen BB, Mäenpää J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacokinet 1995; 39: 151–9Google Scholar
  527. 527.
    Brøsen K. Drug interactions and the cytochrome P450 system: the role of cytochrome P450 1A2. Clin Pharmacokinet 1995; 29: 20–5PubMedGoogle Scholar
  528. 528.
    Carrillo JA, Dahl M-L, Svensson J-O, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60: 183–90PubMedGoogle Scholar
  529. 529.
    Xu Z-H, Xie H-G, Zhou H-H. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996; 42: 518–21PubMedGoogle Scholar
  530. 530.
    Ward ME, Musa MN, Bailey L. Clinical pharmacokinetics of lithium. J Clin Pharmacol 1994; 34: 280–5PubMedGoogle Scholar
  531. 531.
    Firkusny L, Gleiter CH. Maprotiline metabolism appears to cosegregate with genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. Br J Clin Pharmacol 1994; 37: 383–8PubMedGoogle Scholar
  532. 532.
    Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 1995; 15: 399–408PubMedGoogle Scholar
  533. 533.
    Barbhaiya RH, Shukla UA, Kroboth PD, et al. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995; 15: 320–6PubMedGoogle Scholar
  534. 534.
    Barbhaiya RH, Shukla UA, Greene DS, et al. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 1996; 16: 26–34PubMedGoogle Scholar
  535. 535.
    Schmider J, Greenblatt DJ, Von Moltke LL, et al. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 1996; 41: 339–43PubMedGoogle Scholar
  536. 536.
    Barbhaiya RH, Buch AB, Greene DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996; 16: 19–25PubMedGoogle Scholar
  537. 537.
    Kelly JP, E. LB. The contribution of pre-clinical drug evaluation in predicting the clinical profile of the selective serotonin reuptake inhibitor paroxetine. J Serotonin Res 1995; 1: 27–46Google Scholar
  538. 538.
    Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288–95PubMedGoogle Scholar
  539. 539.
    DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994; 55: 38–45Google Scholar
  540. 540.
    Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262–5PubMedGoogle Scholar
  541. 541.
    Metz A, Shader RI. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. International Journal of Clin Psychopharmacol 1990; 5: 191–4Google Scholar
  542. 542.
    Yasui N, Otani K, Kaneko S, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monitor 1995; 17: 333–5Google Scholar
  543. 543.
    Ishida M, Otani K, Kaneko S, et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 1995; 10: 143–6PubMedGoogle Scholar
  544. 544.
    Morton AW, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother 1995; 29: 387–95PubMedGoogle Scholar
  545. 545.
    Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D 6. Br J Clin Pharmacol 1996; 41: 149–56PubMedGoogle Scholar
  546. 546.
    Zhang D, Freeman JP, Sutherland JB, et al. Biotransformation of chlorpromazine and methdilazine by Cunninghamella elegans. App Environ Microbiol 1996; 62: 798–803Google Scholar
  547. 547.
    Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995; 272: 984–90PubMedGoogle Scholar
  548. 548.
    Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate. Am J Psychriatry 1994; 151: 123–5Google Scholar
  549. 549.
    Dahl M-L, Llerena A, Bondesson U, et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacokinet 1994; 37: 71–4Google Scholar
  550. 550.
    Jerling M, Linström L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther Drug Monitor 1994; 16: 368–74Google Scholar
  551. 551.
    Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: A review of recent literature. J Clin Psychopharmacol 1996; 16: 177–87PubMedGoogle Scholar
  552. 552.
    Lam YWF, Jann MW, Chang W-h, et al. Intra- and interethnic variability in reduced haloperidol to haloperidol ratios. J Clin Pharmacol 1995; 35: 128–36PubMedGoogle Scholar
  553. 553.
    Young D, Midha KK, Fossler MJ, et al. Effect of quinidine on the interconversions kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6. Eur J Clin Pharmacol 1993; 44: 433–8PubMedGoogle Scholar
  554. 554.
    Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: Clinical implications and unanswered questions. Clin Psychopharmacol 1994; 14: 159–62Google Scholar
  555. 555.
    Igarashi K, Kasuya F, Fukui M, et al. Studies on metabolism of haloperidol (HP): The role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following IP administration of HP. Life Sci 1995; 57: 2439–46PubMedGoogle Scholar
  556. 556.
    Dahl-Puustinen M-L, Lidén A, Aim C, et al. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78–81PubMedGoogle Scholar
  557. 557.
    Linnet K. Comparison of the kinetic interactions of the neuroleptics perphenazine and zuclopentihixol with tricyclic anti-depressives. Ther Drug Monitor 1995; 17: 308–11Google Scholar
  558. 558.
    Jerling M, Dahl M-L, Åberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996; 59: 423–8PubMedGoogle Scholar
  559. 559.
    Linnet K, Wiborg O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 1996; 60: 41–7PubMedGoogle Scholar
  560. 560.
    Sallee RF, Pollock BG, Stiller RL, et al. Pharmacokinetics of pimozide in adults and children with Tourettes syndrome. J Clin Pharmacol 1987; 27: 776–81PubMedGoogle Scholar
  561. 561.
    Flockhart DA, Richard E, Woosley RL, et al. A metabolic interaction between clarithromycin and pimozide may result in cardiac toxicity. Clin Pharmacol Ther 1996; 59: 189Google Scholar
  562. 562.
    Huang M-L, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1996; 54: 257–68Google Scholar
  563. 563.
    von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49: 234–40Google Scholar
  564. 564.
    Blake BL, Rose RL, Mailman RB, et al. Metabolism of thioridazine by microsomal monooxygenases; relative roles of P450 and flavin-containing monooxygenase. Xenobiotica 1995; 25: 377–93PubMedGoogle Scholar
  565. 565.
    Eap CB, Guentert TW, Schäublin-Loidl M, et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996; 59: 322–31PubMedGoogle Scholar
  566. 566.
    Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52: 479–86PubMedGoogle Scholar
  567. 567.
    von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Alprazolam metabolism in vitro: studies of man, monkey, mouse and rat liver microsomes. Pharmacology 1993; 47: 268–76Google Scholar
  568. 568.
    Yasui N, Koichi O, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996; 59: 514–9PubMedGoogle Scholar
  569. 569.
    Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989; 16: 337–64PubMedGoogle Scholar
  570. 570.
    von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23–31Google Scholar
  571. 571.
    Jajoo HK, Blair IA, Klunk LJ, et al. In vitro metabolism of the antianxiety drug buspirone as a predictor of its metabolism in vivo. Xenobiotica 1990; 20: 779–86PubMedGoogle Scholar
  572. 572.
    Breimer DD. Clinical pharmacokinetics of hypnotics. Clin Pharmacokinet 1977; 2: 93–109PubMedGoogle Scholar
  573. 573.
    Seree EJ, Pisano PJ, Placidi M, et al. Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol 1993; 7: 69–75PubMedGoogle Scholar
  574. 574.
    Rey E, dAthis P, Giraux P, et al. Pharmacokinetics of clorazepate in pregnant and nonpregnant women. Eur J Clin Pharmacol 1979; 15: 175–80PubMedGoogle Scholar
  575. 575.
    Greenblatt DJ, Divoll MK, Soong MH, et al. Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. J Clin Pharmacol 1988; 28: 853–9PubMedGoogle Scholar
  576. 576.
    Bertilsson L, Henthorn TK, Sanch E, et al. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989; 45: 348–55PubMedGoogle Scholar
  577. 577.
    Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994; 56: 471–6PubMedGoogle Scholar
  578. 578.
    Yasumori T, Qing-Hua L, Yamazoe Y, et al. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4-hydroxylation. Pharmacogenetics 1994; 4: 323–31PubMedGoogle Scholar
  579. 579.
    Luurila H, Olkkola KT, Neuvonen PJ. Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacol Toxicol 1996; 78:117–22PubMedGoogle Scholar
  580. 580.
    Machinist JM, Bopp BA, Anderson DJ. Metabolism of 14C-estazolam in dogs and humans. Xenobiotica 1986; 16: 11–20PubMedGoogle Scholar
  581. 581.
    Mancinelli A, Guiso G, Garattini S, et al. Kinetic and pharmacological studies on estazolam in mice and man. Xenobiotica 1985; 15: 257–65PubMedGoogle Scholar
  582. 582.
    Greenblatt DJ, Divoll M, Harmatz JS, et al. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 1981; 30: 475–86PubMedGoogle Scholar
  583. 583.
    Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981; 6: 89–105PubMedGoogle Scholar
  584. 584.
    Mastey V, Donati F, Varin F. Early pharmacokinetics of midazolam: Sampling site and schedule considerations. Clin Pharmacokinet 1995; 9: 131–40Google Scholar
  585. 585.
    Olkkola KT, Aranko K, Luurila H, et al. Apotentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298–305PubMedGoogle Scholar
  586. 586.
    Kupferschmidt HHT, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20–8PubMedGoogle Scholar
  587. 587.
    Thummel KE, OShea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491–502PubMedGoogle Scholar
  588. 588.
    Kronbach T, Mathys D, Umeno M, et al. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA 4. Mol Pharmacol 1989; 36: 89–96PubMedGoogle Scholar
  589. 589.
    Olkkola KT, Ahonen J, Neuvonen PJ. The effect of systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996; 82: 511–6PubMedGoogle Scholar
  590. 590.
    Patel M, Tang BK, Grant DM, et al. Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. Pharmacogenetics 1995; 5: 287–97PubMedGoogle Scholar
  591. 591.
    Simons PJ, Cockshott ID, Douglas EJ, et al. Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. Xenobiotica 1988; 18: 429–40PubMedGoogle Scholar
  592. 592.
    Le Guellec C, Lacarelle B, Villard P-H, et al. Glucuronidation of propofol in microsomal fractions from various tissues and species including humans: Effect of different drugs. Anesth Analg 1995; 81: 855–61PubMedGoogle Scholar
  593. 593.
    Ahonen J, Olkkola KT, Neuvonen PJ. Lack of effect of anti-mycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther Drug Monitor 1996; 18: 124–7Google Scholar
  594. 594.
    von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketaconazole. J Pharmacol Exp Ther 1996; 276: 370–9Google Scholar
  595. 595.
    Hukkinen SK, Varhe A, Olkkola KT, et al. Plasma concentrations of triazolam are increase by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995; 58: 127–31PubMedGoogle Scholar
  596. 596.
    Kinirons MT, Lang CC, He HB, et al. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and southern asians: ethnicity and CYP3A activity. Br J Clin Pharmacol 1996; 41: 69–72PubMedGoogle Scholar
  597. 597.
    Phillips JP, Antal EJ, Smith RB. A pharmacokinetic interaction between erythromycin and triazolam. J Clin Psychopharmacol 1986; 6: 297–9PubMedGoogle Scholar
  598. 598.
    Pichard L, Gillet G, Bonfils C, et al. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos 1995; 23: 1253–62PubMedGoogle Scholar
  599. 599.
    Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995; 29: 142–53PubMedGoogle Scholar
  600. 600.
    Gentile DM, Tomlinson ES, Maggs JL, et al. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996; 277: 105–12PubMedGoogle Scholar
  601. 601.
    Schuetz JD, Schuetz EG, Thottassery JV, et al. Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol Pharmacol 1996; 49: 63–72PubMedGoogle Scholar
  602. 602.
    Back DJ, Orme MLE. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990; 18: 472–84PubMedGoogle Scholar
  603. 603.
    OConnell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995; 35: 18S–24SGoogle Scholar
  604. 604.
    Schubert W, Eriksson U, Edgar B, et al. Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17β-estradiol. Eur J Drug Metab Pharmacokinet 1995; 20: 219–24PubMedGoogle Scholar
  605. 605.
    Guengerich FP. Oxidation of 17-α-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33: 500–8PubMedGoogle Scholar
  606. 606.
    Ebner T, Remmel R, Burchell B. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol Pharmacol 1993; 43: 649–54PubMedGoogle Scholar
  607. 607.
    Goldhzieher JW, Brody SA. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol 1990; 163: 2114–9Google Scholar
  608. 608.
    Huskey S-EW, Dean DC, Miller RR, et al. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos 1995; 23: 1126–35PubMedGoogle Scholar
  609. 609.
    Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 1996; 30: 16–27PubMedGoogle Scholar
  610. 610.
    Berson A, Wolf C, Chachaty C, et al. Metabolic activation of the nitroaminic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther 1993; 265: 366–72PubMedGoogle Scholar
  611. 611.
    Fotherby K. Levonorgestrel: Clinical pharmacokinetics. Clin Pharmacokinet 1995; 28: 203–15PubMedGoogle Scholar
  612. 612.
    Vitas M, Rozman D, Komel R, et al. P450-mediated progesterone hydroxylation in Cochliobolus lunatus. J Biotech 1995; 42: 145–50Google Scholar
  613. 613.
    Utaaker E, Lundgren S, Kvinnsland S, et al. Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer. J Steroid Biochem 1988; 31: 437–41PubMedGoogle Scholar
  614. 614.
    Marthrubutham M, Fotherby K. Medroxyprogesterone acetate in human serum. J Steroid Biochem 1981; 14: 783–6Google Scholar
  615. 615.
    Lonning PE, Lien EA, Lundgren S, et al. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 1992; 22: 327–58PubMedGoogle Scholar
  616. 616.
    Fleming GF, Amato JM, Agresti M, et al. Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chemother Pharmacol 1992; 29: 445–9PubMedGoogle Scholar
  617. 617.
    Camaggi CM, Strocchi E, Martoni A, et al. Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies. Cancer Chemother Pharmacol 1995; 36: 356–9PubMedGoogle Scholar
  618. 618.
    Lew KH, Ludwig EA, Milad MA, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993; 54: 402–14PubMedGoogle Scholar
  619. 619.
    Harris RZ, Tsunoda SM, Mroczkowski P, et al. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 1996; 59: 429–35PubMedGoogle Scholar
  620. 620.
    Jönsson G, Aström A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 1995; 23: 137–42PubMedGoogle Scholar
  621. 621.
    Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990; 19: 126–46PubMedGoogle Scholar
  622. 622.
    Aoyama T, Yamano S, Waxman DJ, et al. Cytochrome P450 hPCN3, a novel cytochrome P-450 III A gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989; 264: 10388–95PubMedGoogle Scholar
  623. 623.
    Vandenbrom RHG, Wierda JMKH, Agoston S. Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. Clin Pharmacokinet 1990; 19: 230–40PubMedGoogle Scholar
  624. 624.
    Agoston S, Vandenbrom RHG, Wierda JMKH. Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet 1992; 22: 94–115PubMedGoogle Scholar
  625. 625.
    Kharasch ED, Thummel KE, Mautz D, et al. Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 1994; 55: 434–40PubMedGoogle Scholar
  626. 626.
    Garton KJ, Yuen P, Meinwald J, et al. Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. Drug Metab Dispos 1995; 23: 1426–30PubMedGoogle Scholar
  627. 627.
    Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993; 79: 795–807PubMedGoogle Scholar
  628. 628.
    Kharasch ED, Armstrong AS, Gunn K, et al. Clinical sevoflurane metabolism and disposition: II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. Anesthesiology 1995; 82: 1379–88PubMedGoogle Scholar
  629. 629.
    Pendyala L, Creaven PJ. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial. Cancer Epidemiol Biomarkers Prev 1995; 4: 245–51PubMedGoogle Scholar
  630. 630.
    Lin C, Magat J, Calesnick B, et al. Absorption, excretion and urinary metabolic pattern of 3H-albuterol aerosol in man. Xenobiotica 1972; 2: 507–15PubMedGoogle Scholar
  631. 631.
    Morgan DJ, Pauli JD, Rchmond BH, et al. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br J Clin Pharmacol 1986; 22: 587–93PubMedGoogle Scholar
  632. 632.
    Gaudry SE, Sitar DS, Smyth DD, et al. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin Pharmacol Ther 1993; 54: 23–7PubMedGoogle Scholar
  633. 633.
    Wong LTY, Sitar DS, Aoki FY. Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. Br J Clin Pharmacol 1995; 39: 81–4PubMedGoogle Scholar
  634. 634.
    Sallerin-Caute B, Lazorthes Y, Monsarrat B, et al. CSF baclofen levels after intrathecal administration in severe spasticity. Eur J Clin Pharmacol 1991; 40: 363–5PubMedGoogle Scholar
  635. 635.
    Tassaneeyakul W, Birkett DJ, McManus ME, et al. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994; 47: 1767–76PubMedGoogle Scholar
  636. 636.
    Miners JO, Birkett DJ. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol 1996; 27: 245–9PubMedGoogle Scholar
  637. 637.
    Olsen H, Koppang E, Alvn G, et al. Carisoprodol elimination in humans. Ther Drug Monitor 1994; 16: 337–40Google Scholar
  638. 638.
    Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192–209PubMedGoogle Scholar
  639. 639.
    Kim RB, OShea D, Wilkinson GR. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 1995; 57: 645–55PubMedGoogle Scholar
  640. 640.
    Ono S, Hatanaka T, Hotta H, et al. Chloroxazone is metabolized by human liver CYP1A2 as well as by human CYP2E1. Pharmacogenetics 1995; 1995: 143–50Google Scholar
  641. 641.
    Markham A, Bryson HM. Epoetin alfa: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 1995; 49: 232–54PubMedGoogle Scholar
  642. 642.
    Ball SE, Maurer G, Zollinger M, et al. Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans. Drug Metab Dispos 1992; 20: 56–63PubMedGoogle Scholar
  643. 643.
    Brockmöller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet 1994; 27: 216–48PubMedGoogle Scholar
  644. 644.
    Matsumoto H, Matsubayashi K, Fukui Y. Evidence that cytochrome P-4502E1 contributes to ethanol elimination at low doses: Effects of diallyl sulfide and 4-methyl pyrazole on ethanol elimination in the perfused rat liver. Alcohol Clin Exp Res 1996; 20: 12A-16AGoogle Scholar
  645. 645.
    Asai H, Imaoka S, Kuroki T, et al. Microsomal ethanol oxidizing system activity by human hepatic cytochrome P450s. J Pharmacol Exp Ther 1996; 277: 1004–9PubMedGoogle Scholar
  646. 646.
    Sass JO, Masgrau E, Saurat J-H, et al. Metabolism of oral 9-cis-retinoic acid in the human identification of 9-cis-retinoyl-β-glucuronide and 9-cis-4-oxo-retinoyl-β-glucuronide as urinary metabolites. Drug Metab Dispos 1995; 23: 887–91PubMedGoogle Scholar
  647. 647.
    Schwartz EL, Hallam S, Gallagher RE, et al. Inhibition of alltrans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem Pharmacol 1995; 50: 923–8PubMedGoogle Scholar
  648. 648.
    Raner GM, Vaz ADN, Coon MJ. Metabolism of all-trans, 9-cis, and 13-cis isomers of retinal by purified isozymes of microsomal cytochrome P450 and mechanism-based inhibition of retinoid oxidation by citral. Mol Pharmacol 1996; 49: 515–22PubMedGoogle Scholar
  649. 649.
    Larsen FG, Nielsen-Kudsk F, Jakobsen P, et al. Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases. Clin Pharmacokinet 1992; 23: 42–61PubMedGoogle Scholar
  650. 650.
    Leo MA, Lasker JM, Raucy JL, et al. Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC 8. Arch Biochem Biophys 1989; 269: 305–12PubMedGoogle Scholar
  651. 651.
    Martini R, Murray M. Participation of P450 3A enzymes in rat hepatic microsomal retinoic acid 4-hydroxylation. Arch Biochem Biophys 1993; 303: 57–66PubMedGoogle Scholar
  652. 652.
    Young IM, Leone RM, Francis P, et al. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J Clin Endocrinol Metab 1985; 60: 114–9PubMedGoogle Scholar
  653. 653.
    Vakkuri O, Tervo J, Luttinen R, et al. A cyclic isomer of 2-hydroxymelatonin: A novel metabolite of melatonin. Endocrinology 1987; 120: 2453–9PubMedGoogle Scholar
  654. 654.
    Mallo C, Zaidan R, Galy G, et al. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol 1990; 38: 297–301PubMedGoogle Scholar
  655. 655.
    Berkman C, Park SB, Wrighton SA, et al. In vitro-in vivo correlations of human (S)-nicotine metabolism. Biochem Pharmacol 1995; 50: 565–70PubMedGoogle Scholar
  656. 656.
    Benowitz NL, Jacob III P, Fong I, et al. Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994; 268: 296–303PubMedGoogle Scholar
  657. 657.
    Nakajima M, Yamamoto T, Nunoya K-I, et al. Characterization of CYP2A6 involved in the 3-hydroxylation of cotinine in human liver microsomes. J Pharm Exp Ther 1996; 277: 1010–5Google Scholar
  658. 658.
    Rames A, Poirier J-M, LeCoz F, et al. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther 1990; 47: 354–9PubMedGoogle Scholar
  659. 659.
    Weber A, de Groot R, Ramsey B, et al. Probenecid pharmacokinetics in cystic fibrosis. Dev Pharmacol Ther 1991; 16: 7–12PubMedGoogle Scholar
  660. 660.
    Scott AK. Sumatriptan. Clinical pharmacokinetics. Clin Pharmacokinet 1994; 27: 337–44PubMedGoogle Scholar
  661. 661.
    Spaldin V, Madden S, Pool WF, et al. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 1994; 38: 15–22PubMedGoogle Scholar
  662. 662.
    Spaldin V, Madden S, Adams DA, et al. Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 1995; 23: 929–34PubMedGoogle Scholar
  663. 663.
    Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995; 28: 449–57PubMedGoogle Scholar
  664. 664.
    Harland CC, Steventon GB, Marsden JR. Thalidomide-induced neuropathy and genetic differences in drug metabolism. Eur J Clin Pharmacol 1995; 49: 1–6PubMedGoogle Scholar
  665. 665.
    Chen T-L, Vogelsang GB, Petty BG, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 1989; 17: 402–5PubMedGoogle Scholar
  666. 666.
    Braun AG, Harding FA, Weinreb SL. Teratogen metabolism: Thalidomide activation is mediated by cytochrome P-450. Toxicol Appl Pharmacol 1986; 82: 175–9PubMedGoogle Scholar
  667. 667.
    Knoche B, Blaschke G. Stereoselectivity of the in vitro metabolism of thalidomide. Chirality 1994; 6: 221–4Google Scholar
  668. 668.
    Tröger U, Meyer FP. Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline: focus on biotransformation. Clin Pharmacokinet 1995; 28: 287–314PubMedGoogle Scholar
  669. 669.
    Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39: 321–326PubMedGoogle Scholar
  670. 670.
    Zhang Z-Y, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 1995; 50: 205–11PubMedGoogle Scholar
  671. 671.
    Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: Inhibition studies. J Pharmacol Exp Ther 1996; 276: 912–7PubMedGoogle Scholar
  672. 672.
    Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769–72PubMedGoogle Scholar
  673. 673.
    Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes: mechanisms and management. Drugs 1994; 47: 51–65PubMedGoogle Scholar
  674. 674.
    Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36: 233–52Google Scholar
  675. 675.
    Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995; 15: 387–98PubMedGoogle Scholar
  676. 676.
    Shen WW. Cytochrome P450 monoxygenases and interactions of psychotropic drugs: a five year update. Int J Psychiatry Med 1995; 25: 277–90PubMedGoogle Scholar
  677. 677.
    Bertilsson L, Dahl M-L. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200–23Google Scholar
  678. 678.
    Glue P, Banfield C. Psychiatry, psychopharmacology and P-450s. Hum Psychopharmacol 1996; 11: 97–114Google Scholar
  679. 679.
    Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 1993; 71: 1002–9PubMedGoogle Scholar
  680. 680.
    DArcy PF, Griffin JP. Interactions with drugs used in the treatment of depressive illness. Adverse Drug React Toxicol Rev 1995; 14: 211–31Google Scholar
  681. 681.
    Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: A look behind the mirror. Int Clin Psychopharmacol 1995; 10: 15–21PubMedGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.Department of Pharmacokinetics and Biopharmaceutics, Dept. Number 4PK, Building AP13AAbbott LaboratoriesAbbott ParkUSA

Personalised recommendations